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ABSTRACT 
 
The innate immune system must differentiate homeostatic cell stress and death 
from that associated with danger and infection. Failure to do so can lead to inflammatory 
disorders and autoimmunity on one hand, or cancer and infection on the other. Various 
endogenous host factors are proposed to tolerize or activate the immune system in 
response to cell stress/death. Antigen presenting cells (APCs), in particular dendritic cells 
(DC), are critical in the induction and direction of the immune response, including 
responses to cell stress/death. Many endogenous molecules influence APC activation in a 
paracrine manner following exposure to stressed/dying cells. Conversely, stress within an 
APC can modulate how it directs an immune response. This thesis focuses on (1) 
characterizing a novel pathway of increased cell-surface expression of calreticulin that 
occurs concomitantly with secretion of several other endogenous proteins previously 
defined as immunomodulatory; (2) using this pathway to examine the abilities of ER 
chaperones to influence innate immune responses in the context of ER stress, with a 
specific focus on calreticulin; (3) measuring the ability of cell-surface calreticulin to 
promote phagocytic uptake of ER stressed cells by DC; (4) comparing cytokine 
production by DCs experiencing two different forms of ER stress. 
 Much recent attention has been focused on the ability of cell-surface calreticulin 
to induce anti-tumor immune responses to dying tumor cells. We characterize a novel 
stimulus, thapsigargin, and the related pathway for the induction of high levels of cell-
  xi 
surface calreticulin. Thapsigargin depletes ER calcium, inducing ER stress and a general 
handicap in ER retention mechanisms. Thapsigargin-treated cells secrete several ER 
chaperones previously characterized as immunomodulatory. We show that extracellular 
calreticulin does not modulate the ability of DCs to secrete inflammatory cytokines under 
sterile conditions or in the presence of an innate immune stimulus such as LPS. On the 
other hand, DC phagocytosed ER-stressed target cells significantly more than untreated 
control targets. Furthermore, the presence of cell-surface calreticulin on target cells 
correlated with their enhanced phagocytic uptake. Together these findings demonstrate 
that calcium depletion in the ER interferes with retention mechanisms of ER-resident 
proteins and impacts phagocytic uptake of cells in a calreticulin-dependent manner.
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CHAPTER ONE 
Introduction 
 
Endoplasmic Reticulum (ER): calcium homeostasis, protein folding chaperones, and 
protein retention 
 
The ER is the birthplace of virtually all secreted, transmembrane and some 
organelle-targeted proteins, and an important coordination center for many cell-signaling 
pathways (reviewed in (Braakman and Bulleid, 2010; Gorlach et al., 2006)). Most 
secretory proteins are co-translationally transported into the ER. Normally, the ER aids 
its large volume of diverse protein clientele in folding, by actively providing an 
appropriate folding environment. This environment includes a host of folding chaperones, 
oxidative conditions to allow disulfide bond formation, and sufficient concentration of 
calcium and ATP to promote secretory protein folding (Braakman and Bulleid, 2010; 
Gaut and Hendershot, 1993). The ER achieves a homeostatic luminal calcium 
concentration thousands of times greater than that found in the cytosol in large part using 
two main features. First, active cytosol to ER calcium transport is driven by 
transmembrane Ca
2+
 pumps that are members of the Sarco(Endo)plasmic Reticulum Ca
2+
 
ATPases (SERCAs). Second, the ER membrane is largely impermeable to most 
molecules and tightly controls transport of other molecules (Braakman and Bulleid, 2010; 
Burdakov et al., 2005). The relatively high calcium concentration facilitates protein 
folding, and provides a sub-cellular Ca
2+
 gradient that is important in cell signaling 
(Gorlach et al., 2006). Consequently, the ER must also be able to vary its calcium 
concentration widely. The ER and the mitochondria are the two principal calcium-
buffering organelles. Many ER resident proteins function in storing Ca
2+
 via calcium 
binding, adding another level of control to the regulation of cellular [Ca
2+
] (Gorlach et 
al., 2006). ER-resident proteins that participate in calcium storage include gp96 (grp94 or 
  
 2 
endoplasmin), protein disulfide isomerase (PDI), calreticulin (CRT), and 
immunoglobulin-heavy-chain-binding protein (BiP/GRP78). CRT is one of the most 
important intra-lumenal calcium regulators. gp96, PDI, CRT and BiP are highly 
expressed in the ER and contain multiple Ca
2+
 binding sites, thereby providing a large 
capacity of calcium storage (Braakman and Bulleid, 2010; Burdakov et al., 2005; Gorlach 
et al., 2006).  
Interestingly, gp96, PDI, CRT and BiP are also ER folding factors, aiding newly 
synthesized ER proteins in proper folding. Calcium is required for proper protein folding 
for several reasons. First, calcium ions play a structural role in some proteins (e.g. some 
extracellular matrix proteins (Handford, 2000)) that traffic via the secretory pathway 
(Braakman and Bulleid, 2010)). Secondly, calcium binding by ER folding factors affects 
their structure in a concentration-dependent manner. Consequently, the functions of ER 
folding factors are affected by fluctuations in [Ca
2+
] (Michalak et al., 2002; Rizvi et al., 
2004). By altering ER folding factor function, variations in [Ca
2+
] affect the folding of 
many client proteins (Gorlach et al., 2006; Michalak et al., 2002). Like most ER folding 
factors, BiP, PDI, gp96 and CRT, are also molecular chaperones. Molecular chaperones 
can directly bind to unfolded regions of protein clients preventing them from co-
aggregating with other unfolded proteins. This binding alone can aid folding of nascent 
proteins. Some folding factors, such as ERp57 and PDI are oxidoreductases that catalyze 
proper disulfide bond formation in protein substrates to aid in their folding (Braakman 
and Bulleid, 2010).  
In many cases, chaperones act co-operatively to locate, engage and fold nascent 
proteins. The calnexin (CNX)/CRT cycle is an example of chaperone co-operation to 
ensure quality control for all asparagine (N)-linked glycoproteins. CNX is a 
transmembrane molecular chaperone that is similar to CRT. Newly synthesized N-linked 
glycoproteins initially have a specific oligosaccharide structure that is added to N-linked 
glycosylation sites during or shortly following their translocation into the ER. This 
oligosaccharide has three terminal glucose residues, and is the universal starting 
carbohydrate moiety on all N-linked glycoproteins. The carbohydrate is also the signal 
that will be modified to indicate the protein folding status as proper folding progresses. 
Two terminal glucose residues are sequentially removed by glucosidases I & II. 
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CNX/CRT both specifically recognize and bind to glycan-processed monoglucosylated 
proteins. When clients are released from the complex with CNX/CRT, glucosidase II 
cleaves the terminal glucose. A glycoprotein without a terminal glucose residue is 
allowed to proceed through the secretory pathway. On the other hand, if the released 
client is not fully folded, it is recognized by a protein folding sensor, UDP-glucose 
glycoprotein glucosyl-transferase (UGGT) and a monoglucosylated glycan is 
regenerated. This modification allows CRT or CNX to bind the client and inhibit its 
secretion. Failure to fold after prolonged retention within the CNX/CRT cycle results in 
the protein being targeted for ER-associated degradation (ERAD) (reviewed in (Michalak 
et al., 2009)). Another layer of cooperation results in the recruitment of the thiol-
oxidoreductase ERp57 to incompletely folded proteins by the specific interaction of 
ERp57 with CRT and CNX. By binding CRT/CNX, ERp57 is able to isomerize incorrect 
disulfide bonds of CNX/CRT-associated glycoproteins (reviewed in (Braakman and 
Bulleid, 2010)). 
The collective actions of the ER folding factors execute quality control for all 
protein clients in the ER. This function is an important post-translational checkpoint that 
prevents expression of mutant gene products that could be harmful to the organism 
(Ellgaard et al., 1999). This is accomplished mainly by retention of incompletely folded 
proteins and degradation of terminally mis-folded proteins. Molecular chaperones 
selectively recognize and bind incompletely folded clients not only to aid in their folding, 
but also to ensure their retention in the ER (Braakman and Bulleid, 2010). Terminally 
mis-folded proteins are targeted for degradation through ERAD (reviewed in (Hebert et 
al., 2010)). Aggregation can also prevent ER exit of misfolded proteins. When the ER 
succeeds in properly folding protein clients, they escape recognition by chaperones and 
are actively transported to the cis-Golgi and subsequently continue to mature throughout 
the secretory pathway, often culminating in secretion or expression on the cell-surface 
(reviewed in (Braakman and Bulleid, 2010)).  
The selective retention of fully folded ER-resident proteins and associated 
unfolded protein clients contrasts with the active export of fully folded client proteins. 
This presents a sorting problem for the ER. Many questions about how the ER overcomes 
this problem remain unanswered, but several mechanisms to retain ER-resident proteins 
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are understood in significant detail (reviewed in (Pfeffer, 2007; Sato and Nakano, 2007)). 
One mechanism involves the recognition and active sorting of folded protein cargo into 
specific transport vesicles that are coated with dedicated coat protein complexes (COP). 
COPII coated vesicles form at ER exit sites (ERES) and transport ER secretory cargo to 
the cis Golgi (reviewed in (Braakman and Bulleid, 2010; Sato and Nakano, 2007)). 
Generally, this type of sorting is dependent on signals found in the amino acid (aa) 
sequence of the proteins destined for export from the ER, and/or post-translational 
modifications of these proteins (Dancourt and Barlowe, 2010; Sato and Nakano, 2007). 
Some signals involved for targeting transmembrane proteins are characterized, and are 
located in the cytoplasmic domain of transmembrane protein clients (Sato and Nakano, 
2007). In order for these same signals to concentrate soluble proteins into the ERES and 
COPII vesicles, the soluble proteins must bind to specific transmembrane ER cargo 
receptors (Dancourt and Barlowe, 2010; Sato and Nakano, 2007). In this case, additional 
signals in the soluble proteins and/or post-translational modifications must direct the 
soluble cargo to specific cargo receptors (Dancourt and Barlowe, 2010). A variety of ER 
cargo receptors have been identified. Current research suggests that different cargo 
receptors transport different soluble cargo. In some cases, the signals directing a cargo 
molecule to its appropriate cargo receptor are known. Characterized cargo recognition 
signals include general features of cargo proteins such as various oligosaccheride 
moieties, amino acid motifs and secondary structures (Dancourt and Barlowe, 2010). 
Known cargo:receptor binding is regulated by pH, receptor oligomerization, and/or 
calcium concentration (reviewed in (Dancourt and Barlowe, 2010)). Given the multi-
layered control in concentrating secretory proteins at ERES, residence in the ER may be 
the default scenario for proteins entering the ER, folding properly, yet lacking an export 
signal. However, a percentage of a given protein not targeted for concentration at ERES 
does slowly escape from the ER (Braakman and Bulleid, 2010; Pfeffer, 2007). This rate 
of export is referred to as ‘bulk flow.’ It is believed that bulk flow contributes to the 
intended secretion of some protein cargo (Dancourt and Barlowe, 2010), but is suggested 
to be relatively inefficient (Sato and Nakano, 2007). 
The cell uses a second mechanism to properly localize ER-resident proteins 
escaping due to bulk flow: retrieving escaped proteins from the Golgi (the downstream 
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organelle in the secretory pathway). ER-resident proteins have a consensus KDEL motif, 
recognized by a KDEL receptor residing primarily in the Golgi. The KDEL receptor 
binds proteins harboring a version of the KDEL sequence in a manner influenced by pH, 
and retrieves such proteins back to the ER through retrograde transport (reviewed in 
(Pfeffer, 2007)). Working together, these two described mechanisms generally maintain 
ER ‘residence’ of chaperones and co-chaperones (Pfeffer, 2007). There may be other 
unidentified and under studied mechanisms for ER retention (Pfeffer, 2007; Sonnichsen 
et al., 1994). One interesting hypothesis proposed over 20 years ago is that the high 
concentration of calcium in the ER allows numerous calcium-binding ER resident 
proteins to form a calcium-dependent matrix that holds the contents of the ER in place 
(Sambrook, 1990). This hypothesis may be relevant to findings described in chapter 2. 
 
Failed retention of ER chaperones 
 In most cases, describing a protein as ‘ER resident’ refers to the majority of that 
protein. A minority of a given ER chaperone is often discovered outside the ER upon 
examination by sensitive methods. Papers published over the last 20 years from a variety 
of research groups characterize physiological and pathophysiological situations wherein 
‘ER-resident’ chaperones are found in non-ER locations. An increasing number of 
functions have been attributed to ER chaperones in the extracellular space, but in many 
cases, functions are not yet fully described. Similarly, the mechanism of ER escape is not 
fully defined. This brief discussion will focus on chaperones that escape ER retention via 
the secretory pathway. 
 ER chaperones escape ER retention for a variety of reasons. ER chaperones 
escape has been characterized during particular developmental stages of a cell, and in 
specialized secretory cell types. In immature thymocytes, many, but not all newly 
synthesized ER proteins, including BiP, CRT, CNX & gp96, escape ER retention (Wiest 
et al., 1997). These chaperones were all found on the surface of immature but not mature 
thymocytes. Other examples include the release of ER chaperones in specialized, highly 
secretory cell types, like thyrocytes (Mezghrani et al., 2000) and pancreatic acinar cells 
(Bruneau et al., 2000). Thyrocytes and pancreatic acinar cells are responsible for 
secreting high levels of thyroglobulin and digestive enzymes, respectively. In both of 
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these cases, ER chaperones such as BiP, gp96 and PDI are reported to escape while 
bound to the primary secretory cargo, and associate with incompletely folded cargo 
molecules (Bruneau et al., 2000; Mezghrani et al., 2000). PDI has been reported to be a 
plasma membrane component of B lymphocytes with over representation in B cell 
chronic lymphocytic leukemia (Kroning et al., 1994; Tager et al., 1997). In another case, 
the chaperone CRT escapes in a different specialized cell type, cytotoxic T-cells. 
Cytotoxic T-cells kill target cells by release of cytotoxic granules following specific 
stimulation. In activated cytotoxic T-cells, CRT was exocytosed from intracellular 
granules along with perforins and granzyemes following immune recognition of target 
cells (Dupuis et al., 1993; Sipione et al., 2005). 
 Extracellular presence of ER chaperones is relatively uncommon. Related to this, 
some studies report humoral immune responses to ER chaperones in some disease states. 
For example, in a 2001 study by Bla! et al., sera from rheumatoid arthritis (RA) patients 
was reported to more frequently (252/400) contain anti-BiP auto-antibodies in 
comparison with sera from patients with other rheumatic diseases (14/200) or healthy 
controls (1/150) (Blass et al., 2001). Furthermore, in sera from lupus patients, 13/34 
samples had anti-CRT auto-antibodies, whereas no anti-CRT antibodies were detected in 
healthy control serum (Eggleton et al., 2000). Both necrotic and shrunken apoptotic cells 
(Franz et al., 2007) can non-specifically release ER proteins (i.e. release ER proteins in a 
way that is not specific to a particular ER protein or subset of ER proteins. Instead this 
refers to a general release of the contents of the ER or the cell). It is possible in these 
disease states, BiP & CRT are released at higher levels than in healthy individuals due to 
tissue damage resulting from cell death in diseased individuals. It is also possible that 
autoimmune responses are developed against the ER chaperones when present in the 
extracellular space. The question remains whether these anti-chaperone autoimmune 
responses are indicative of a role for chaperones in disease pathogenesis, or whether 
observed responses against them were merely a consequence of a higher propensity for 
autoimmune responses in a diseased individual. The potential contribution of 
extracellular chaperones to autoimmunity will be discussed in chapter 4. 
As expected, genetic (Elrod-Erickson and Kaiser, 1996) or pharmacological (Di 
Jeso et al., 2005) interference with ER quality control is another way to disrupt retention 
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of proteins that are normally retained in the ER. As discussed in this section, highly 
secretory cells sometimes release ER chaperones. A demanding secretory load can 
challenge the ER quality control mechanisms described earlier. However, even in 
physiological situations of high secretory load, only a relatively small fraction of the total 
pool of a given ER chaperone is found to escape ER retention. We will now consider how 
cells manage an increased secretory load in an attempt to meet the increased demands of 
their quality control pathways. 
 
ER response to stress (UPR)  
 
One third of all open reading frames in the human genome are predicted to encode 
proteins destined for the ER. It is a challenge for the ER to accomplish its protein folding 
functions (Braakman and Bulleid, 2010). Furthermore, various physiological and 
pathophysiological changes can compound the challenge by either increasing the demand 
for secreted products (e.g., cellular differentiation, or virus infection) or by interfering 
with protein folding (e.g., ER calcium depletion, oxidative damage, energy depletion) 
(Malhotra and Kaufman, 2007). The quantity of protein clients requiring folding 
assistance sometimes overwhelms the folding capacity of the ER at any given time, 
leading to an accumulation of misfolded/unfolded proteins and ER stress. Eukaryotic 
cells are equipped with a specific response pathway to recognize an accumulation of 
unfolded proteins and attempt to restore ER homeostasis (reviewed in (Schroder and 
Kaufman, 2005; Todd et al., 2008)). This pathway is called the unfolded protein response 
(UPR). 
The mammalian UPR has 3 axes mediated by 3 separate, ER-localized 
transmembrane proteins: activating transcription factor 6 (ATF6), inositol-requiring 
transmembrane kinase/endonuclease1 (IRE1) and pancreatic ER kinase (PERK) (Todd et 
al., 2008). Under resting conditions, these proteins are bound by the multi-functional, 
ER-resident molecular chaperone, BiP, maintaining them in an inactive state. When 
unfolded proteins accumulate in the ER, BiP is recruited to aid their folding and to 
prevent protein aggregation, allowing the proximal signaling molecules (ATF6, IRE1, 
and PERK) the potential to become activated. Activated IRE1 activates the transcription 
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factor X-box binding protein 1 (XBP-1) by splicing its mRNA, leading to production of 
the active form of the protein: XBP-1s. Activated ATF6 is cleaved, freeing the fragment 
ATF6f that is a transcription factor. Activated PERK inactivates (through 
phosphorylation) the eukaryotic translation-initiation factor (EIF2") and induces 
expression of the transcription factor ATF4. These transcription factors orchestrate the 
UPR (Todd et al., 2008). 
The UPR uses several strategies to deal with an excess of misfolded proteins. The 
three described UPR-activated transcription factors induce expression of three different 
sets of UPR target genes: ER-stress response elements (ERSEs) by ATF6f, and two 
different sets of UPR elements (UPREs) activated by XBP1s and ATF4 (Todd et al., 
2008). ATF6f and XBP1s increase expression of molecular chaperones that assist in 
protein folding, and of machinery and raw materials (i.e., lipids) necessary for increasing 
the quantity of ER in the cell (Todd et al., 2008). ATF6f also induces expression of genes 
responsible for ERAD, thereby reducing the quantity of unfolded proteins in the ER. 
PERK-mediated phosphorylation of EIF2", complements the induction of ERAD by 
blocking translation of most cellular mRNAs. The ATF4 mRNA bypasses this 
translational block by having upstream open reading frames (uORFs) that recruit 
phosphorylated EIF2" (Todd et al., 2008). In addition to using uORFs, mRNAs encoding 
proteins important for the stress response, including many molecular chaperones, avoid 
translational block through various mechanisms (reviewed in (Yamasaki and Anderson, 
2008)). As suggested, there is a great deal of interplay, and some redundancy among the 
signaling networks employed by the three axes of the UPR (reviewed in (Todd et al., 
2008)).  
Because many forms of cell stress also lead to the accumulation of unfolded 
proteins, there is also a great degree of interplay and redundancy in the cellular response 
to a diverse array of insults. For example, hypoxia (Blais et al., 2004; Koumenis et al., 
2002), oxidative stress, and glucose starvation all typically induce protein misfolding, and 
are shown to induce some or all of the UPR signaling pathways described above 
(Malhotra and Kaufman, 2007). Furthermore, in addition to unfolded proteins, different 
types of cell stress can lead to elevated levels of reactive oxygen species (ROS) and 
depleted levels of ER calcium (Gorlach et al., 2006; Malhotra and Kaufman, 2007). 
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Reciprocally, ROS can induce ER calcium depletion (Gorlach et al., 2006) and ER 
calcium depletion can induce ROS (Hsieh et al., 2007). But ROS, misfolded proteins, and 
ER calcium depletion have unique features as well that are likely dependent on the 
kinetics with which each stimulus induces various responses. If severe enough, each of 
these stimuli can result in cell death (Gorlach et al., 2006). It should be emphasized, 
however, that even in the absence of cell stress, calcium levels flux naturally within the 
ER to maintain cellular calcium homeostasis and transducing intracellular signals 
(Gorlach et al., 2006).  
 
ER stress, inflammation and autoimmunity 
 
Due to the stressful nature of inflammatory conditions, it is logical that there 
would be connections between inflammation and the cell stress response. In fact, the ER 
stress response is connected to inflammation in a diverse range of diseases: 
atherosclerosis, inflammatory bowel disease, diabetes, obesity and inflammatory 
neurodegenerative disorders (reviewed in (Hummasti and Hotamisligil, 2010; Yoshida, 
2007)). There are several proposed mechanisms that link ER stress and these 
inflammatory conditions. Diseases, and/or associated mouse models, including idiopathic 
inflammatory myopathies, ankylosing spondylitis, inflammatory colitis, and experimental 
autoimmune encephalomyelitis implicate an insufficient UPR in several different ways as 
a cause or contributor to disease development (Todd et al., 2008). Another mechanism is 
proposed for autoimmune diseases like lupus (Eggleton et al., 2000) and rheumatoid 
arthritis (Blass et al., 2001; Corrigall et al., 2001), where extracellular UPR chaperones 
are suggested to be autoantigens and/or adjuvants promoting the autoimmune response.  
Related to connections between the UPR and inflammatory conditions, recent 
work revealed that UPR signaling pathways not only exhibit cross talk between 
themselves, but also with innate immune signaling pathways responsible for detecting 
infectious agents (Martinon et al., 2010; Smith et al., 2008; Zhang et al., 2006). Zhang et 
al. identified a liver-specific transcription factor, CREBH, which is activated by ER 
stress, and is responsible for expression of acute phase response genes (Zhang et al., 
2006). Acute phase response genes are upregulated in the liver during infection and in the 
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systemic inflammatory element of innate immunity (Yoo and Desiderio, 2003). Zhang et 
al. established a novel, mechanistic link between ER stress and innate immunity 
occurring in the liver by showing that CREBH and ATF6 form heterodimers and 
synergistically enhance their target genes required for the acute phase response and UPR, 
respectively (Zhang et al., 2006). They also showed UPR activation in hepatocytes 
following addition of lipopolysaccharide (LPS, an activator of the pathogen recognition 
receptor toll-like receptor (TLR)-4) or upon addition of pro-inflammatory cytokines IL-6 
and IL-1!.    
Subsequent research extended the connections between ER stress and the innate 
immune response identified in the liver, to antigen presenting cells (APC) (Martinon et 
al., 2010; Smith et al., 2008). APC are found throughout the body and are responsible for 
initiating and directing the immune response. Smith et al. showed that macrophages 
subject to two different types of pharmacologically-induced ER stress responded to the 
pathogen associated molecular patterns (PAMPs), LPS and poly(I:C) (TLR-3 ligand), 
with enhanced production of the pro-inflammatory cytokine, interferon-! (IFN-!) (Smith 
et al., 2008). Furthermore, they showed that the synergy between TLR stimulation and 
ER stress induced by ER calcium depletion (induced by thapsigargin) was independent of 
PERK expression but dependent on XBP-1. Finally, macrophages from transgenic rats 
expressing the human MHC-I allotype (HLA-B27), which is prone to misfolding, also 
produced significantly (~4 fold) more IFN-! than control cells in response to LPS (Smith 
et al., 2008). These examples demonstrate connections between ER stress and the innate 
immune response. 
Martinon et al. identified new connections between ER stress and innate 
immunity, in addition to extending the findings described above (Martinon et al., 2010). 
They showed that XBP-1 was activated following ligation of TLRs 2, 4 and 5 (but not 3, 
7, 8 and 9). Unexpectedly however, TLR-2 and TLR-4 ligation actively dampened other 
signals associated with UPR activation. For example, TLR-4 activation did not activate 
the other two arms of the UPR, ATF-6 and PERK. Therefore, PRR ligation activated one 
arm of the ER stress response pathway, but did not induce an ER stress response. 
Martinon et al. also examined the relationship between XBP-1 activation in 
response to PRR ligation and inflammatory cytokine production. Consistent with the 
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previously defined role for XBP-1 to synergistically enhance IFN-! production (Smith et 
al., 2008), XBP-1 expression was required for wild-type levels of pro-inflammatory 
cytokine production. Finally, the relevance of XBP-1 to infection was confirmed by 
showing that cytokine production and the innate immune response to the intracellular 
bacteria, F. tularensis, was impaired in XBP-1
-/-
 macrophages and mice respectively 
(Martinon et al., 2010). The precise mechanism used by XBP-1 to synergize with innate 
immune responses is still unknown (Martinon et al., 2010). In conclusion, there is an 
important synergy between ER stress within an antigen presenting cell (APC) and the 
innate immune response directed by that APC. In this thesis (chapter 3), I address the 
related question of how APCs respond to cell stress in a tissue-derived cell that it 
encounters. 
 
The immune response to stressed, dying and dead cells 
  
Unlike professional APCs, other cell types are incapable of orchestrating immune 
responses, such as initiating or preventing an adaptive immune response to specific 
peptides and proteins (Savina and Amigorena, 2007). Therefore, it is necessary for APCs 
(particularly dendritic cells (DCs)) to sense infection or danger in surrounding cells or 
tissues and deliver information about potential danger (or lack thereof) to the other 
components of the immune system (Schenten and Medzhitov, 2011). APCs translate 
danger/infection into an immune response using both innate and adaptive immunity 
(Savina and Amigorena, 2007). APCs also promote tolerance of the adaptive immune 
response to peptides/proteins not associated with danger/infection (Morel and Turner, 
2011). Consequently, in addition to cell stress influencing an APC’s function directly as 
discussed in the previous section, cell stress could also alter the immune response by 
influencing APCs in a paracrine manner. This paracrine influence could occur at the level 
of the innate, the adaptive, or both arms of the immune response. 
Innate immune activation to danger/infection involves the recognition of a limited 
number of fixed molecular patterns found in self-molecules associated with tissue 
damage (or ‘danger’ DAMPs) (Zitvogel et al., 2010) or foreign molecules from 
pathogens (PAMPs) (Schenten and Medzhitov, 2011) by pattern recognition receptors 
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(PRRs). Activation of PRRs results in the production of pro-inflammatory signals, such 
as cytokines and chemokines that activate surrounding cells and recruit other leukocytes. 
These innate signals instruct any ensuing adaptive immune response (Schenten and 
Medzhitov, 2011). To briefly summarize, the induction of an adaptive immune response 
requires an APC to first be activated by a danger/infection signal (Gallucci et al., 1999; 
Schenten and Medzhitov, 2011)). Immature APCs constantly survey their surrounding 
tissue by phagocytosing material that is targeted for uptake (opsonized), such as apoptotic 
cells or bacteria (Savina and Amigorena, 2007). APCs in peripheral tissues regularly 
migrate to draining lymph nodes to present processed peptides bound to MHC-I and II 
molecules to CD8+ and CD4+ T-cells, respectively (Savina and Amigorena, 2007). Some 
APC subsets reside in lymph nodes and are responsible for capturing and/or presenting 
soluble and cell-associated antigens that drain to the lymph node or which are carried to 
the lymph node by other types of APC (Allenspach et al., 2008; Asano et al., 2011; Lee et 
al., 2009). The source for APC-presented peptides are from those proteins expressed 
within the APC or cells/proteins phagocytosed by the APC. If the APC was exposed to 
any maturation stimuli (pro-inflammatory cytokines, PAMPs, or other ‘danger’ signals) it 
matures, and undergoes phenotypic changes. These phenotypic changes include up-
regulation of T-cell co-stimulatory molecules on the cell surface, and expression of 
surface proteins which direct the APC into lymph nodes (Savina and Amigorena, 2007). 
Naïve T-cells specific for peptide:MHC complexes (usually foreign peptides) presented 
by mature APCs expressing co-stimulatory molecules will be primed (Blander, 2008). 
The primed, activated T-cells will carry out the adaptive immune response, including 
activation of antigen specific B-cells. 
If an APC in the lymph node was not first exposed to maturation stimuli it will 
not express the co-stimulatory molecules required to activate naïve T-cells. T-cells 
specific to the peptide:MHC complexes (usually self peptides) presented in the absence 
of co-stimulation will become anergic or undergo apoptosis (clonal deletion) (Morel and 
Turner, 2011). Alternatively, in the presence of specific inhibitory signals (e.g., TGF-! 
and IL-10), a DC presenting self-peptides may induce T-cells to become regulatory cells. 
Regulatory cells actively suppress immune responses to their cognate peptide:MHC 
complexes. Induction of both T-regulatory cells and T-cell anergy are important 
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mechanisms in promoting peripheral tolerance to self-antigens (Morel and Turner, 2011). 
Central tolerance is the deletion of most developing self-reactive thymocytes prior to 
leaving the thymus (Kyewski and Klein, 2006). Together, peripheral and central tolerance 
work in tandem in an attempt to avoid autoimmunity (Kyewski and Klein, 2006; Morel 
and Turner, 2011). 
Several questions arise relating to abilities of stressed cells to modulate an 
immune response through interactions with APCs. These include (i) what types of 
stressed cells (i.e., what types of stress) exhibit paracrine immune modulation (ii) what 
signals exchanged between the stressed cell and APC are relevant (iii) are the stressed 
cells immunosuppressive or pro-inflammatory and how does the type of stress influence 
the response and (iv) can stressed cells modulate the innate and/or adaptive immune 
response? 
Cell death is the outcome of unresolved cell stress. Therefore, characterizing the 
signals released from cells dying as a result of different stresses is important in 
understanding the immune response to stresses. In fact, current research shows the type 
of cell stress that eventually leads to cell death alters a dying cell’s immunological 
properties in the context of anti-tumor immunity (Zitvogel et al., 2010). Additionally, it is 
not always easy or experimentally possible to arrest cells at a particular stage as they 
travel along the continuum from viability, to stress and finally death. Consequently there 
is a great degree of overlap in understanding immunomodulation by stressed cells and 
dying cells. 
 
Modulation of the innate immune response by dying cells 
For many years, there were primarily two types of cell death recognized and 
studied: necrosis and apoptosis. Cells dying by apoptosis are characterized 
morphologically by chromatin condensation, blebbing of the cell membrane, cell 
shrinkage, and maintenance of organelle and plasma membrane integrity (Cohen et al., 
1992; Kerr et al., 1972). Unlike apoptosis, cells dying by necrosis swell, and lose 
structural integrity of outer membranes and organelle resulting of the leakage of 
intracellular molecules (Kung et al., 2011). The immunological consequences of the 
signals released from or exposed by these two types of dead and dying cells are 
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classically thought to be quite distinct. Apoptotic and necrotic cells are generally 
considered to be immunosuppressive and highly inflammatory, respectively (Gallucci et 
al., 1999; Rock and Kono, 2008).  
However, like necrotic cells, apoptotic cells eventually lose membrane integrity 
and are thought to non-specifically release intracellular contents.  These ‘late’ apoptotic 
cells are often referred to as secondary necrotic cells. Observations (some occurring over 
30 years ago) associating delayed clearance of apoptotic cells with lupus (autoimmune 
disease) patients also suggested similarities between late apoptotic and necrotic cells 
(reviewed in (Schulze et al., 2008)). Consequently, these observations led to the 
widespread adoption of a ‘clearance deficiency’ (Schulze et al., 2008) as a major factor 
driving the development of autoimmune diseases. Deficiency in the clearance of 
apoptotic cells is proposed to promote auto-immunity primarily through three 
mechanisms. First, interaction of apoptotic cells with phagocytes is dominantly 
immunosuppressive, which aids in prevention of autoimmune responses. Second, late 
apoptotic cells and their released intracellular contents are proposed to be pro-
inflammatory. Third, increased exposure of intracellular contents, allows more 
opportunities for the intracellular contents to be presented inappropriately as antigens in a 
stimulatory context (Elliott and Ravichandran, 2010).  
However, the putative immunogenic nature of late apoptotic cells and their 
released contents is contradicted by some observations. For example, in some in vitro 
studies, apoptotic cells did not become inflammatory or remained dominantly 
immunosuppressive after progressing to late apoptosis (Patel et al., 2006; Ren et al., 
2001). Furthermore, some knockout mouse models have defective apoptotic cell 
clearance yet show no signs of inflammation or auto-immunity (Devitt et al., 2004; Stuart 
et al., 2005). However, these are less common than mouse models that have both signs of 
apoptotic cell clearance deficiency and autoimmunity (reviewed in (Elliott and 
Ravichandran, 2010)). More recent studies suggest that tissue-specific variations exist in 
the receptors used for clearing apoptotic cells (Rodriguez-Manzanet et al., 2010) and the 
type of immune response to apoptotic cell-associated antigens (i.e., immunogenic vs. 
tolerogenic) (Asano et al., 2011). This may explain some of the inconsistencies in studies 
of the immunogenicity of late apoptotic cells. Altogether, these studies suggest that 
  
 15 
context is an important factor when considering the immune response to dying cells 
(reviewed in (Elliott and Ravichandran, 2010)).  
Many studies also demonstrate that the cell stress/death stimulus leading to cell 
death is a critical factor determining the strength of an anti-tumor immune response to 
dying tumor cells (reviewed in (Zitvogel et al., 2010)). Results from these studies do not 
conform with the classical immunomodulatory designations of apoptotic and necrotic 
cells being immunosuppressive and inflammatory, respectively (Zitvogel et al., 2010). 
Several molecules are suggested to be determinants of the immunogenicity of cell death. 
These include: phosphatidylserine (PS), HMGB1, CRT, ATP/UTP, dsRNA, monosodium 
urate, and IL-1", (reviewed in (Zitvogel et al., 2010)). Some of these molecules are 
believed to directly modulate the innate immune response: HMGB1, dsRNA, 
monosodium urate, and IL-1". The three latter molecules are pro-inflammatory 
(reviewed in (Zitvogel et al., 2010)), whereas HMGB1 is anti-inflammatory in its 
oxidized state and pro-inflammatory in its reduced state (Kazama et al., 2008). Some of 
the dying cell signals aid location and direct or aid uptake of dying cells. Molecules or 
changes in the cell surface that enhance uptake of (opsonize) dying cells, cell debris or 
changes in how the APC perceives dying cells (benign or dangerous) could influence the 
adaptive immune response in multiple ways. These include a quantitative effect on 
antigen levels in APC or on antigen processing and presentation by APC. While 
extracellular CRT is suggested to be an important mediator of immunogenic cell death, 
relevant molecular mechanisms are not understood. Understanding the innate impacts of 
extracellular CRT is a major focus of this thesis.    
 
Modulation of the adaptive immune response by dying cells - clearance of dying 
cells resulting in delivery of cell-associated antigens to APCs for presentation to T-
cells 
The most intimate interaction between an APC and a surrounding cell (or any two 
cells) is when one cell ‘eats’ the neighboring cell either through phagocytic uptake or 
macropinocytosis. This is a common occurrence in vivo due to the high levels of cell 
turnover in humans, and is designed to occur rapidly, allowing efficient clearance of dead 
cells (Elliott and Ravichandran, 2010). Rapid uptake of dead cells allows the body to 
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promptly re-use and recycle the valuable components found in each corpse. As discussed 
previously, prompt removal of apoptotic cells prevents release of their intracellular 
components that may have pathological consequences (Krysko and Vandenabeele, 2008; 
Zitvogel et al., 2010). Phagocytosis is also a critical way for foreign antigens, tumor 
antigens and self-proteins to be delivered to APCs. APCs can then process and present 
cell-derived antigens to T-cells to initiate, prevent or potentiate an adaptive immune 
response. Dead cells are considered to be the only physiological ‘target’ cells for uptake 
by APC. However, some recent in vitro analyses suggest that drug-treated, cancer cells 
can be eaten by APCs well before they show signs of cell death (Obeid et al., 2007b). 
Furthermore, in some experimental and clinical settings, manipulation of certain 
receptor:ligand interactions between a phagocyte and target cell can induce uptake of live 
cells (Chao et al., 2010; Gardai et al., 2005).  
Two models exist describing the mechanism by which innate immune cells take 
up dead/dying cells. In one model, uptake of apoptotic cells occurs via macropinocytosis 
(Hoffmann et al., 2001). In another model, the mechanism of uptake depends on the type 
of cell death experienced by the target cell (Krysko et al., 2006). In contrast with the first 
model, these authors suggest that apoptotic cells are ‘eaten’ using a zipper-like 
phagocytosis resulting in tight, exclusive phagosomes. In contrast, necrotic cells are taken 
up by macropinocytosis, resulting in spacious macropinosomes that include other soluble 
material from the extracellular space (Krysko et al., 2006). Despite these suggested 
differences in the mechanism of uptake, some of the molecular signals responsible for 
inducing recognition and ingestion of various types of dying cells seem to be universal 
(Krysko and Vandenabeele, 2008). The most universal molecular ‘eat-me’ signal is the 
exposure of PS on the outer leaflet of the plasma membrane of dying cells. PS is retained 
on the inner leaflet of the plasma membrane of viable cells and dead cells expose PS on 
the outer layer of the plasma membrane, where it is recognized by a variety of receptors 
and adaptor molecules (reviewed in (Krysko and Vandenabeele, 2008; Ravichandran, 
2010; Zitvogel et al., 2010)). In many experimental systems, PS is the dominant eat me 
signal, and may be sufficient to drive uptake of an apoptotic cell (Ravichandran, 2010). 
In addition to ‘eat-me’ signals like PS, there is great deal of communication 
between the phagocytic prey and the phagocyte (Krysko and Vandenabeele, 2008; 
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Zitvogel et al., 2010). Currently, more is understood about the interactions between 
apoptotic cells (AC) and surrounding cells than necrotic cells (Krysko and Vandenabeele, 
2008), so this discussion will focus on AC:phagocyte interactions. In order to ensure 
prompt removal, AC release ‘find-me’ signals that attract professional phagocytes 
through chemotaxis (which can also be APC) (reviewed in (Munoz et al., 2010)). Find-
me signals include nucleic acids such as ATP & UTP, cleavage products of tyrosyl tRNA 
synthetase, lysophosphatidylcholine, fractalkine (CXC3CL1) and others (Munoz et al., 
2010) (Fig. 1.1). Some of the find-me signals are more limited in their tissue expression 
patterns, like fractalkine and others are universal (ATP/UTP) (Munoz et al., 2010). One 
of the better characterized ‘find-me’ signal receptors includes purinergic receptors (P2Y2 
and P2RX7) (Zitvogel et al., 2010). 
Upon finding a dying cell, a phagocyte will engage eat-me signals displayed on 
the surface of an apoptotic cell with specific receptors. It is interesting that many 
different modes of recognition exist for PS (Fig. 1.1) (Ravichandran, 2010). Some soluble 
molecules are soluble bridging molecules that link PS to other receptors on phagocytes, 
including: milk fat globule protein E8 (MFG-E8), growth arrest-specific gene 6 (Gas-6), 
and protein S (Fig. 1.1). Phagocyte receptors that signal through these PS-dependent 
apoptotic cell opsonins include "5!3 integrin (vitronectin receptor) and the Tyro 3, Axl, 
and Mer family members (TAM family) that bind to MFG-E8 and gas-6, respectively 
(Krysko and Vandenabeele, 2008; Ravichandran, 2010; Zitvogel et al., 2010). Some 
receptors can bind directly to PS, such as the TIM family of receptors (such as TIM4 
(Rodriguez-Manzanet et al., 2010)) and CD14 (Devitt et al., 2004) (Fig. 1.1).  
The relative roles of the different mechanisms of PS recognition and how they 
interact are not entirely elucidated. In some cases, different receptors play only a part in a 
situation where different receptors cooperate to accomplish uptake of a dead cell. For 
example, CD14 (LRP) is suggested to ‘tether’ dying cells to phagocytes by PS binding, 
but not induce uptake (Devitt et al., 2004). In other cases, different receptors are used in 
tissue-specific PS-mediated dead cell clearance (Ravichandran, 2010). Consequently, 
some phagocytes may use different PS receptors to achieve slightly different functional 
outcomes. Therefore, it is interesting to consider the relative functional outcomes of 
ligation of these various receptors, how they interact to recognize what may be a limited 
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number of ligands on a target cell, and how eat-me signals from PS may be integrated 
with those from other eat-me signals (Ravichandran, 2010). 
The second most notable eat-me signal after PS, is the ER chaperone calreticulin 
(Krysko et al., 2006; Zitvogel et al., 2010). CRT’s role as an eat-me signal on the surface 
of an apoptotic cell (Gardai et al., 2005) is a new discovery relative to the eat me signal 
PS (Fadok et al., 1992). The increased expression and redistribution of CRT on the 
surface of pre-apoptotic (prior to PS exposure) and apoptotic (PS positive cells with 
intact plasma membranes) cells is reported to be limited to certain cell death stimuli, 
unlike PS exposure (Zitvogel et al., 2010). Phagocytes are suggested to recognize CRT 
via CD91/LDL-related protein (LRP)/"2-macroglobulin receptor (Gardai et al., 2005). 
Unlike PS, CRT is expressed on the surface of some viable cells (Chao et al., 2010; 
Gardai et al., 2005; Kuraishi et al., 2007; Park et al., 2008). Consequently, viable cells 
express complementary ‘don’t-eat-me’ signals to prevent CRT-mediated uptake (Zitvogel 
et al., 2010). Examples include CD47 (Gardai et al., 2005) and plasminogen activator 
inhibitor-1, PAI-1 (on neutrophils) (Park et al., 2008). Interestingly, blocking CD47 is 
sufficient to drive cell-surface CRT-dependent phagocytic uptake of viable cells by 
macrophages (Chao et al., 2010; Gardai et al., 2005; Park et al., 2008). Furthermore, 
macrophage-mediated uptake of apoptotic cells expressing high levels of both cell 
surface CRT and PS requires CRT:LRP mediated signals in the phagocyte (Gardai et al., 
2005; Park et al., 2008). These findings suggest that CRT is necessary and sufficient to 
drive phagocytic uptake by macrophages (Gardai et al., 2005; Park et al., 2008). CRTs 
function as an eat-me signal on pre-apoptotic cells was demonstrated using BMDC as 
phagocytes (Obeid, 2008; Obeid et al., 2007b). In a pre-apoptotic context, PS is not 
exposed on the PM. Therefore, the relative importance of CRT and PS-mediated uptake 
of apoptotic cells by BMDC is not yet known and is investigated in chapter 3.  
Other eat-me signals could include changes in the glycocalix (cell-surface 
glycoproteins) on shrunken apoptotic cells, and the presence of chaperones such as HSP 
70, HSP90 and gp96. ER chaperones are proposed to bind to a variety of receptors on 
phagocytes. Similarly, apoptotic changes in the glycocalix (Franz et al., 2007) are 
suggested to recruit a variety of binding proteins that promote uptake of dead cells 
(reviewed in (Zitvogel et al., 2010)). Unlike the relatively early exposure of CRT that is 
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seen on dying cells, changes in the glycocalix may appear later in the apoptotic time-line. 
Immature glycoproteins containing ER carbohydrate moieties may be exposed as a result 
of general donation of the ER membrane to the plasma membrane during apoptotic 
blebbing (Franz et al., 2007; Zitvogel et al., 2010).  
In conclusion, various ‘eat-me’ signals, ‘don’t eat-me’ signals, opsonins, 
associated receptors, and many different phagocytes (diversified, for example, by several 
different sub-sets of macrophages & DCs) function to ensure prompt removal of 
apoptotic cells in vivo. Furthermore, signals that accompany the phagocytic event play an 
important role in delivering cell-associated and particulate antigens to APCs for 
presentation to T-lymphocytes. The possibility that various permutations of signals & 
phagocytes combine to alter the way potential antigens are perceived, processed and 
presented is an important area of future research. It will likely further our understanding 
to the adaptive immune response. 
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Figure 1.1 – Find-me and eat-me signals released by apoptotic cells and their 
receptor-mediated detection by phagocytes. 
Find-me signals released from apoptotic cells create a chemotactic gradient detected by 
professional phagocytes. Find-me signals that are described include nucleotides ATP/UTP, 
fractaline (CX3CL1) and lysophosphatidylcholine (LPC), which bind purinergic receptors (P2Y2), 
fractaline receptor (CX3CR1), and G-protein coupled receptor G2A (G2A), respectively. Eat-me 
signals are divided into phosphatidyl-serine (PtdSer)-dependent and DAMP (Danger-associated 
molecular patterns)-dependent mechanisms of uptake. Opsonins such as C1q, surfectant proteins 
A and D (SP-A and SP-D) (not shown) and mannose binding lectin (MBL) bind to immature 
glycoproteins (Schulze et al., 2008; Zitvogel et al., 2010) exposed on the cell surface following 
cell shrinkage as a result of ER membrane donation to the plasma membrane (Franz et al., 2007). 
Because the immature glycoproteins are endogenous molecular patterns recognized by innate 
immune complement proteins, they are classified as DAMPs. LRP(CD91) and the scavenger 
receptors CD14 and CD36 are receptors used by phagocytes to recognize various apoptotic cell 
opsonins (Devitt et al., 2004; Zitvogel et al., 2010). Here the three separate phagocyte receptors, 
LRP, CD14 & CD36 are represented by one symbol. PtdSer-dependent mechanisms of uptake 
include those mediated by bridging molecules like MFG-E8 or Gas6 and dedicated receptors such 
as "v!5 integrin and MER (TAM-family receptors, Mer, Axl, Tyro3) and those mediated by 
direct receptor binding of PS (Bai1, Tim4 or stabilin2) (Elliott and Ravichandran, 2010). Figure 
shown here is edited from: 
 
Elliott, M. R. and K. S. Ravichandran (2010). "Clearance of apoptotic cells: implications in health 
and disease." J Cell Biol 189(7): 1059-1070. 
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The immune response to stressed, dying and dead cells – signals with multiple 
effects on the immune response and future directions 
Interestingly, several of the molecules that control the location and uptake of 
dying cells are also shown to modulate the innate immune response (Munoz et al., 2010; 
Zitvogel et al., 2010). For example, ATP/UTP is pro-inflammatory and, as mentioned, PS 
is anti-inflammatory (reviewed in (Zitvogel et al., 2010)). Other examples include the 
ability of lysophosphatidylcholine (LPC) to enhance phagocytic uptake after being bound 
by IgM molecules, and modulate the innate immune response in addition to serving as a 
find-me signal (Munoz et al., 2010). Other molecules associated with cell stress and death 
are reported to influence the innate immune response, although their effects and modes of 
action are not entirely clear or in some cases are quite controversial. Most notable in this 
later category is the heat-shock protein (HSP) including CRT and other HSPs, which are 
a major focus of this thesis (reviewed in (Henderson et al., 2010; Tsan and Gao, 2009)). 
 
Immunomodulation by heat shock proteins 
 
There is an extensive and controversial history describing the ability of HSPs to 
modulate the immune response. The most essential physiological role of HSPs is to serve 
as molecular chaperones in various intracellular locations. They are so named because 
they are upregulated during conditions of stress (e.g., heat shock) to help the cell cope 
with the stress (Feder and Hofmann, 1999). Several observations led to the attractive 
hypothesis that outside the cell, many HSPs are immunological ‘swiss army knives 
(Schild and Rammensee, 2000),’ including their: intracellular importance during various 
conditions of cell stress; ability to promiscuously bind a wide variety of proteins and 
peptides and induce adaptive immune responses specific to their associated proteins and 
peptides; and apparent stimulation of the innate immune system (Srivastava, 2002).  
Much of the debate regarding their various roles in modulating immune responses 
stems from some of the early work (and still some current publications), in which 
recombinant HSPs expressed in, and purified from bacteria were shown to be 
inflammatory and enhance immune responses to associated or co-administered antigens. 
In these types of experiments it is very difficult to rule out the contribution of 
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contaminating bacterial molecules (Henderson et al., 2010; Tsan and Gao, 2009). The 
innate immune system has evolved an extensive list of receptors PRRs that recognize 
PAMPs, and induce inflammatory responses that initiate and/or direct the immune 
response (Schenten and Medzhitov, 2011). Many of these receptors and signaling 
pathways seem to also respond to specific endogenous ‘danger-associated molecular 
patters’ (DAMPs, also known as alarmins). These pathogen recognition pathways 
(described earlier) are well studied and indisputable relative to HSP’s ability to stimulate 
innate immunity. Consequently, HSP signaling through PRRs provides an attractive 
mechanism to explain their putative pro-inflammatory effects. To further complicate this 
issue, some groups more recently report that HSPs mediate immunosuppression by 
signaling through some of the PRRs ((Zanin-Zhorov et al., 2006) and reviewed in 
(Henderson et al., 2010)). The fact that PAMPs are not classically associated with 
immunosuppression, is used as circumstantial evidence to support the view that some 
reports of immunomodulation by HSPs is independent of contaminating PAMPs 
(Henderson et al., 2010).  
It was not initially known that several of the HSPs bind tightly to PAMPs and 
greatly enhance the immunogenicity of the respective PAMPs (Tsan and Gao, 2009). 
Following recognition of the abilities of HSPs to bind PAMPs, it became recognized that, 
bacterially-derived HSP preparations not only had to be free of contaminating soluble 
PAMPs, but also of HSP-bound PAMPs in order for proposed immunostimulatory 
activities to be credible. A recent review proposed that, and summarized why, HSP-
bound PAMPs explain most, if not all, of the innate immune effects attributed to HSPs 
(reviewed in (Tsan and Gao, 2009)). On the other hand, the possibility that some HSPs 
modulate the innate immune response continues to be supported by current literature 
(Henderson et al., 2010; Murshid et al., 2008; Panayi and Corrigall, 2006; Tamura et al., 
2011; Zitvogel et al., 2010). 
Some HSPs do have a much less disputed role in manipulating the adaptive 
immune response by enhancing the cross priming of associated proteins and/or peptides 
(reviewed in (Murshid et al., 2008; Tsan and Gao, 2009)). CD8+ T-cell priming is the 
activation of a naïve CD8+ T-cell specific to a peptide-MHC-I complex presented by an 
activated professional APC. Cross priming is the presentation of peptides resulting from 
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break down of exogenously-derived proteins not expressed by the APC to allow for 
subsequent APC-mediated T-cell activation. This is highly relevant in the anti-tumor and 
anti-viral immune response (reviewed in (Raghavan et al., 2008)). Srivastava et al. 
showed that vaccination of mice with tumor-derived gp96 protected mice from 
subsequent challenge of the same tumor line but not other tumor lines (Srivastava et al., 
1986). They later showed that vaccination with other tumor-derived HSPs, including 
CRT, displayed the same anti-tumor protection (reviewed in (Srivastava, 2002)).  
Using a technology platform based on these observations and subsequent work, 
Srivastava co-founded a biotechnology company, Agenus (formerly Antigenics) 
(http://www.agenusbio.com/). The legitimacy of an HSP, namely gp96, to induce 
adaptive immune responses to associated antigens is evidenced by successfully clinical 
trials piloted by Agenus (http://www.agenusbio.com/prophage/past-trials.html); most 
notably, a recent, successful, phase III clinical trial using gp96-complexed tumor peptides 
to treat advance melanoma (Testori et al., 2008). This is the focus of Agenus’ current 
work. However, some recent work suggests that this ability of gp96 to dramatically 
enhance cross-priming of T-cells to associated antigens does not occur in the context of 
viral infections (Lev et al., 2009). Furthermore, the ability of gp96 to stimulate innate 
immune responses was questioned as early as 2003 (Reed et al., 2003). As this 2003 
study showed, the ability of gp96 to stimulate ROS and NF#B signaling was dependent 
on contamination with bacterial LPS. However, other responses appeared to be LPS-
independent, consequently, Reed et al. concluded that gp96 (and CRT) were able to 
activate APCs (Reed et al., 2003). Additionally, genetically-induced cell-surface 
expression of gp96 was shown to be immunostimulatory in a transgenic mouse context 
(Liu et al., 2003). Thus, Agenus still includes “HSPs release from dying cells send a 
“danger signal” to the immune system leading to generation of immune responses” as an 
explanation of their technology platform 
(http://www.agenusbio.com/about/platforms.html). Furthermore, their website references 
recent work supporting the idea that gp96 can serve to stimulate innate immune responses 
(Oizumi et al., 2007). Further work is needed to establish in what contexts and using 
which mechanisms gp96 is able to initiate an innate immune response. 
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Similar conflict exists in defining the immunomodulatory properties of the HSP 
BiP. A body of work generated in the UK over the last decade shows that BiP can be 
immunosuppressive, and protects patients against rheumatoid arthritis (RA) (reviewed in 
(Henderson and Pockley, 2010; Panayi and Corrigall, 2006)). Despite the fact that much 
of this work was done using recombinant BiP expressed in bacteria (Corrigall et al., 
2004; Corrigall et al., 2001), this work has culminated in ongoing clinical trials 
evaluating BiP as a treatment for RA (Henderson and Pockley, 2010; Panayi and 
Corrigall, 2008). In contrast with the work describing BiP as an immunsuppressive 
molecule, a very recent paper suggests that BiP derived from tumor cells engineered to 
secrete BiP by deletion of its KDEL sequence is able to cross-prime anti-tumor immune 
responses (Tamura et al., 2011). Although the ability of this secreted BiP to stimulate the 
innate immune response was not directly tested, innate stimulation by BiP was a 
suggested mechanism for enhanced cross-priming of CD8 T-cell responses against 
tumor-associated antigens (Tamura et al., 2011).  
Like BiP, HSP-60 is also reported to be both inflammatory and 
immunosuppressive (reviewed in (Henderson et al., 2010)), although in this case, strong 
evidence suggests that PAMP contamination explains the former observation (Gao and 
Tsan, 2003). Unlike BiP, a receptor through which HSP-60 exerts its immunosuppressive 
effects was identified: TLR-2 (Zanin-Zhorov et al., 2006). Because the HSP-60 used in 
this study was recombinant protein, purified from E. coli, it is interesting to speculate that 
a bacterial PAMP signaling through TLR-2 is responsible for the reported 
immunosuppressive effects. This would be unexpected, as PAMPs are extensively 
characterized as pro-inflammatory signals. However, precedence does exist for the ability 
of PAMPs to suppress rather than stimulate the innate immune response (Frleta et al., 
2009; Ginzkey et al., 2010). Clearly, more work is needed to understand the modulation 
of the innate immune response by BiP and how it may vary in different biological 
contexts. 
CRT is the final HSP to be discussed in depth, and is a central focus of my 
dissertation. Like gp96, Srivastava’s group also described an ability of soluble, tumor-
derived CRT to induce anti-tumor immune responses to associated tumor peptides in 
1999 (Basu and Srivastava, 1999). However, unlike BiP and gp96, many other 
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extracellular functions are attributed to CRT, both immunological and non-
immunological (Gold et al., 2010). Regarding extracellular CRT’s ability to influence 
immune responses, much work starting in 2007 shows that upregulation of CRT on the 
surface of dying tumor cells stimulates protective anti-tumor immune responses (Obeid et 
al., 2007b). Kroemer and colleagues previously showed that anthracyclin-killed tumor 
cells stimulated in vitro maturation of splenic DCs and the induction of adaptive immune 
responses (Casares et al., 2005). These findings suggested that part of the immunogenic 
apoptosis induced by anthracyclin treatment involved both innate and adaptive immune 
activation. However, subsequent work demonstrated that soluble CRT/peptide complexes 
did not stimulate innate or adaptive immune responses to associated peptides (Bak et al., 
2008). This leaves open the possibility that cell-surface CRT is inflammatory, unlike 
soluble CRT. In fact, cell-surface CRT is currently described as a ‘pro-inflammatory’ 
signal by prominent experts in the field, despite no published work to directly test this 
possibility (Zitvogel et al., 2010). Furthermore, Petrovski et al showed that PS-
independent uptake of autophagic cells by macrophages induced pro-inflammatory 
cytokine production (Petrovski et al., 2007a; Petrovski et al., 2007b). They suggested that 
cell-surface calreticulin may be the signal responsible for the PS-independent uptake and 
the pro-inflammatory cytokine production, but these hypotheses have yet to be tested 
(Petrovski et al., 2007a; Petrovski et al., 2007b). Currently, the relative contributions of 
an innate immune response (possibly stimulated by cell-surface CRT) vs. the delivery of 
cell-associated antigen (by enhancing uptake of apoptotic cells) in cell-surface CRT-
dependent anti-tumor immunity have not been characterized, studies that are undertaken 
in my thesis.  
 
Calreticulin, a traveling multi-functional protein  
CRT is a soluble protein found predominantly found in the ER. In the ER, CRT 
serves as a chaperone for all N-linked glycoproteins. CRT binds proteins mainly through 
recognition of mono-glucosylated glycans (Hebert and Molinari, 2007). CRT can also 
bind and prevent aggregation of non-glycosylated protein clients in vitro (Hebert and 
Molinari, 2007; Jeffery et al., 2011; Rizvi et al., 2004; Saito et al., 1999). The functional 
contribution of the polypeptide based chaperone activity of CRT to protein folding in 
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vivo is debated and still unclear. This uncertainty is in part due to the inability to pinpoint 
a polypeptide-binding site on CRT (Jeffery et al., 2011).  
CRT comprises 3 domains: a globular N-domain, an extended arm-like P-domain, 
and an acidic C-terminal tail (‘C-domain’) (Michalak et al., 2009) (Fig. 1.2). The globular 
domain contains the lectin binding site, the proposed polypeptide binding site (Leach et 
al., 2002), and a single high-affinity Ca
2+
 binding site (Kozlov et al., 2010). The C-
domain has a low affinity, high capacity Ca
2+
 binding site that is reported to bind over 
50% of the calcium found in the ER (Michalak et al., 2009). The P-domain is proline rich 
and suggested to have some structural flexibility (Michalak et al., 2009). CRT uses the tip 
of the P-domain to bind its partner co-chaperone, ERp57 (Michalak et al., 2009). 
Specifically, CRT requires amino acid W244 of the P-domain to bind ERp57 (Del Cid et 
al., 2010; Frickel et al., 2002). As previously mentioned, CRT and ERp57 co-operate in 
properly folding client glycoproteins in the ER (Frickel et al., 2002).  
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Figure 1.2 – Calreticulin’s molecular structure 
Generated in MacPyMOL 
 
CRT is also one of a select group of five ER chaperones or specific assembly 
factors that are responsible for the proper folding and peptide loading of MHC-I 
molecules. A complex formed by these proteins is designated the ‘peptide-loading 
complex’ (PLC). MHC-I molecules are expressed by all nucleated cells and are required 
for CD8 T-cell immune responses against intracellular pathogens and tumor cells 
(Raghavan et al., 2008). CRT is bound to ERp57 both inside and outside the PLC.  
In addition to its roles in the ER, CRT is found in several other sub-cellular 
locations: the cytosol, cis-golgi and plasma membrane (Gold et al., 2010). In resting cells, 
a portion of CRT is retrotranslocated into the cytosol in an atypical manner that avoids 
proteasomal degradation (Afshar et al., 2005; Carpio et al., 2010). Here it is suggested to 
aid in cell adhesion (Afshar et al., 2005) and gene transcription (reviewed in (Michalak et 
al., 2009)). Additionally, during conditions of cell stress such as cell calcium depletion, 
cytoplasmic arginylated-CRT associates with stress granules (Carpio et al., 2010). The 
specific function of CRT in the stress granules is not known. Like other ER-localized 
proteins, a portion of CRT escapes ER retention, and is mostly retrieved by the KDEL 
receptor in the Golgi. Recently, Howe et al showed that the CRT that is recycled from the 
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Golgi back to the ER is responsible for retrieving sub-optimally loaded MHC-I molecules 
(Howe et al., 2009). In doing so, CRT molecules recycling in the early secretory pathway 
promote optimal loading on MHC-I (Howe et al., 2009). Unlike these later two examples 
of CRT functions in specific locations outside the ER, many functions are reported for 
extra-cellular CRT, including roles in cellular adhesion, cell migration, anoikis, 
phagocytosis, inflammation, cell signaling, and enhancing wound healing and anti-tumor 
immune responses (Gold et al., 2010).  
Of central interest to my thesis are the proposed abilities of cell-surface CRT to 
enhance phagocytosis (Gardai et al., 2005), induce inflammation and promote anti-tumor 
immune responses (Cheng et al., 2005; Obeid et al., 2007b). In 2005, Kroemer and 
colleagues first published the finding that anthracyclin-induced tumor cell apoptosis 
drove protective, anti-tumor immune responses in mice (Casares et al., 2005). 
Anthracyclins are a class of chemotherapeutics. This finding was surprising because 
apoptotic cells were previously known to be strongly immunosuppressive in many other 
contexts examined. In 2007, Kroemer and colleagues showed that anthracyclins also 
induced the highest levels of cell-surface calreticulin among a panel of 14 different 
cytotoxic drugs (some of which were chemotherapeutics) (Obeid et al., 2007b). 
Furthermore, anthracyclin-induced immunogenicity of cell death required cell-surface 
calreticulin. Kroemer et al. showed that cell surface calreticulin was strongly upregulated 
within a few hours of drug treatment, long before PS exposure. For this and other 
reasons, anthracyclin-induced upregulation of cell-surface CRT was suggested to be a 
pre-apoptotic event (Obeid et al., 2007b). Subcutaneous immunization with the CRT-high 
pre-apoptotic cells provided mice with almost complete protection from subsequent 
tumor challenge, and protection was dependent on cell-surface CRT. Furthermore, the 
immunization with surface CRT-high cells primed IFN-$ producing cells in the draining 
lymph node in a surface CRT dependent manner (Obeid et al., 2007b). This experiment 
suggested a direct involvement of CRT in generating the adaptive anti-tumor immune 
response. However, many related questions about CRT-dependent stimulation of the 
adaptive immune response remain unanswered, including: whether extracellular CRT 
drives an advantageous (in the context of anti-tumor immunity) innate immune response 
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and whether a CRT advantage resulting from tumor cell phagocytosis can translate into 
increased priming of T-cell responses against tumor cell antigens. 
 
Overall summary 
 To begin to address the questions outlined above, we tested different conditions 
for extracellular CRT exposure in chapter 2, including cell treatments with an 
anthracyclin, UV irradiation and different types of ER stress. We showed that THP-
induced, ER calcium depletion handicaps ER retention, resulting in the release of several 
proteins normally retained within the ER. Most notably, ER calcium depletion induced 
strong cell-surface calreticulin. THP induced cell-surface CRT to an extent greater than 
that induced by anthracyclins. This finding allowed us to identify mechanisms of cell-
surface CRT exposure in THP-treated cells in chapter 2. Additionally, in chapter 3, we 
characterized functional impacts of stress-induced cell-surface CRT upon the innate 
immune response focusing on cytokine production and target cell phagocytosis by DC. In 
chapter 4, we summarize the findings of chapters 2 and 3 and discuss the implications of 
this work in understanding the effects of cell stress on ER protein retention, antigen 
delivery and innate immunity. 
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CHAPTER TWO 
Specific forms of endoplasmic reticulum stress break ER retention and strongly 
increase cell-surface calreticulin 
 
SUMMARY 
A number of immunological functions are ascribed to cell-surface expressed 
forms of the endoplasmic reticulum (ER) chaperone CRT, including abilities to induce 
inflammation and adaptive anti-tumor immune responses. Here we examined the impact 
of several different ER stress inducing stimuli on cell-surface CRT induction. We show 
that cell-surface expression of CRT and secretion of CRT, BiP, gp96 and PDI are induced 
by THP treatment, which depletes ER calcium, but not by tunicamycin (TUN) treatment, 
which inhibits protein glycosylation. We define the mechanism of THP-induced, CRT 
surface expression, and show that it is distinct from the two previously described 
mechanisms of cell-surface CRT expression. Binding sites relevant to the polypeptide-
specific chaperone activity of CRT are important for the retention of CRT on the cell 
surface. We also show cell-surface expression of CRT on apoptotic but not viable plasma 
cells, a cell type under constitutive ER stress resulting from high secretory load. Other 
apoptotic cells examined, including splenocytes and thymocytes, do not show elevated 
levels of surface CRT as assessed by flow cytometry. Together, our data show that 
increased cell surface CRT expression by a magnitude measurable by flow cytometry is 
linked to certain type of drug-induced and physiological forms of ER stress. Sections of 
this chapter were published in:  
Peters, L.R., and Raghavan, M. (2011). Endoplasmic reticulum calcium depletion 
impacts chaperone secretion, innate immunity, and phagocytic uptake of cells. J Immunol 
187, 919-931. 
and 
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Jeffery, E., L. R. Peters, and M. Raghavan. 2011. The polypeptide binding 
conformation of CRT facilitates its cell-surface expression under conditions of 
endoplasmic reticulum stress. J Biol Chem 286:2402-2415. 
 
INTRODUCTION 
 The endoplasmic reticulum (ER) is an important site of protein folding, calcium 
storage, and intracellular signaling (Gorlach et al., 2006). A number of ER chaperones 
are important in carrying out these functions. CRT is a chaperone that maintains quality 
control of glycoprotein folding by binding mono-glucosylated proteins in the ER. CRT 
also contributes to calcium storage in the ER (reviewed in (Michalak et al., 2009)). 
Several recent studies showed that the cell-surface expression of CRT was induced in 
different cell types by different treatments, and that the increased amount and/or the re-
distribution of CRT on the cell surface has important functions in the immune response 
(reviewed in (Gold et al., 2010; Green et al., 2009)). In 2005, Gardai et al. first 
characterized that CRT was upregulated and re-distributed on the surface of UV-treated, 
apoptotic cells. Cell surface CRT was necessary for phagocytic uptake of apoptotic cells. 
Although the mechanism for CRT upregulation and re-distribution was not defined in the 
study, the authors did show that CRT and PS co-localized in distinct clusters on the 
apoptotic cell surface (Gardai et al., 2005).  
 In the following years two different models were published explaining the 
increased surface expression of CRT in dying cells. The most recent model, involves the 
subset of CRT molecules demonstrated to reside in the cytosol (arriving via non-
degrading retrotranslocation from the ER), in resting viable cells (Afshar et al., 2005; 
Carpio et al., 2010). In 2010, Tarr et al. proposed that the cytosolic portion of cellular 
CRT associates with PS on the inner leaflet of the plasma membrane in a manner that is 
enhanced by calcium (Tarr et al., 2010). Furthermore, Tarr et al. suggested that following 
the exposure of PS on the outer leaflet during apoptosis or pharmacological intervention, 
PS-bound CRT becomes exposed. This study did not directly address the contribution of 
a loss in membrane integrity due to secondary necrosis or oxidative damage to the cell 
surface expression of CRT (Tarr et al., 2010). 
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 The other proposed model is described in many papers from the laboratory of Dr. 
Guido Kroemer. Their studies characterized chemotherapeutic drugs and relevant 
pathways that lead to increased cell-surface CRT expression. They showed increased co-
dependent surface expression of CRT/ERp57 complexes in pre-apoptotic cells at 
relatively short time points following exposure to UV light, gamma-irradiation, 
anthracyclin chemotherapeutics (e.g., mitoxantrone (MTX)), and platinum-based 
chemotherapeutics (e.g., oxaliplatin) (Obeid, 2008; Obeid et al., 2007a; Obeid et al., 
2007b; Panaretakis et al., 2008a; Panaretakis et al., 2009; Tufi et al., 2008). In addition, 
activation of pancreatic ER kinase (PERK), which initiates one of three branches of the 
unfolded protein response, induction of reactive oxygen species, pre-apoptotic cleavage 
of caspase 8, activation of pro-apoptotic molecules, BAX and BAK (Panaretakis et al., 
2009), and ER calcium efflux (Panaretakis et al., 2009; Tufi et al., 2008) are required. 
Notably, BAX and BAK lead to ER calcium efflux and alterations in mitochondrial 
membrane permeability (Scorrano et al., 2003).  
 A number of other studies also suggest links between ER calcium depletion and 
detection of ER-resident proteins, including CRT, in the extracellular space. Treatment of 
NIH3T3 cells with the calcium ionophore A23167, which depletes intracellular calcium 
stores (Drummond et al., 1987), resulted in secretion of gp96, an ER-resident chaperone, 
and reduced intracellular levels of CRT (referred to in the paper as CRP55) (Booth and 
Koch, 1989). Furthermore, treatment of NIH3T3 cells with the sarco-endoplasmic 
reticulum Ca
2+
-ATPase (SERCA) inhibitor THP (Thastrup et al., 1990) resulted in a 
decrease in CRT ER staining intensity and an increase in the co-localization of CRT with 
wheat germ agglutinin in a non-ER cellular compartment suggested to be the Golgi 
(Booth and Koch, 1989). Finally, two other groups showed that ER calcium depletion by 
THP results in secretion and surface expression of BiP (Delpino and Castelli, 2002; 
Zhang et al., 2010).  
THP is a commonly used drug to induce the UPR pathway, and as noted above, 
THP induces calcium depletion (Thastrup et al., 1990). Another drug that is commonly 
used to induce the UPR pathway is TUN, which inhibits protein glycosylation thereby 
causing protein misfolding in the ER (Rutkowski and Kaufman, 2004). Both TUN and 
THP induce all three axes of the UPR including PERK activation, which is required for 
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pre-apoptotic, anthracyclin-induced surface CRT:ERp57 complex expression (Li et al., 
2000; Martinon et al., 2010; Martins et al., 2011).  
In the present studies, we compare the impacts of these two ER stress-inducing 
drugs as well as the chemotherapeutic MTX, on cell-surface expression of CRT in 
different cell types. We show that cell-surface expression of CRT, and secretion of other 
ER proteins including CRT, is specific to the ER calcium depletion-induced form of ER 
stress. Cell-surface expression of CRT in THP treated cells involves a failure in effective 
ER retention mechanisms for a number of ER-resident proteins. Furthermore, amino acid 
residues that contribute to the polypeptide-specific chaperone activity of CRT also 
influence its surface expression in THP-treated cells (Jeffery et al., 2011). This mode of 
CRT release from the ER is distinct from that described for anthracyclin-induced surface 
CRT expression, where co-translocation with ERp57 is suggested and other ER proteins 
are not secreted (Obeid, 2008; Panaretakis et al., 2008a).  
Finally, splenocyte differentiation into plasma cells is used as a physiological 
model of constitutive ER stress based on previous findings that the UPR-induced 
transcription factor XBP-1 is required for plasma cell differentiation (Iwakoshi et al., 
2003). Indeed B-cell to plasma cell differentiation is characterized by expression of the 
expansion of the ER (Kirk et al., 2010). We report that surface CRT is not found on 
viable plasma cells during the days following initiation of differentiation. However, in 
contrast with other apoptotic cells examined, apoptotic plasma cells showed elevated 
levels of surface CRT. Together, our data show that increases in cell surface CRT 
expression that are measurable by flow cytometry are a feature of some but not all 
apoptotic cells and are consistent with a model in which both ER chaperone upregulation 
and reduction in ER calcium levels are required to liberate resident chaperones from ER 
retention. 
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METHODS 
Drugs and antibodies 
TUN and MTX were purchased from Calbiochem or Sigma, and used at 10 µg/ml or 1 
µM, respectively unless indicated otherwise. THP was purchased from both Sigma and 
Alexis Biochemicals (now Enzo Life Sciences) and used at 5 µM, unless indicated 
otherwise. MTX, THP and TUN were all dissolved in DMSO and stored in single use 
aliquots at -20
o 
C at stock concentrations of 1 mM, 5 mM and 10 mg/ml, respectively. 
Frozen aliquots and freshly dissolved drugs did not show differences in measured 
activities. Chicken-anti-CRT or rabbit-anti-CRT were purchased from Affinity 
Bioreagents, now part of Thermo Scientific (PA1-902A), and Abcam (ab2907), 
respectively and used for flow cytometry at a concentration of 2.5 µg/ml and a dilution of 
1:200, respectively. Annexin-V (AnnV)-FITC was purchased from Biovision and BD 
biosciences. 7AAD was purchased from Sigma. Mouse-anti-H2b (Y3) (1:100) and 
mouse-anti-H2d (34-1-2S) (1:100) were used to detect MHC-I in flow cytometry, and 
rabbit anti-K
b
 antiserum EX8 (P8) (1:6000) was used in MHC-I immunoblots (kindly 
provided by Dr. Jonathan Yewdell). Streptavidin-APC (BD biosciences, 554067) was 
used at a 1:100 dilution. All other fluorescent secondary antibodies were purchased from 
Jackson Immunoresearch. For immunoblots, goat-anti-CRT (Santa Cruz, sc-7431) was 
used at a dilution of 1:2500, and secondary antibodies conjugated to horseradish 
peroxidase were purchased from Jackson Immunoresearch and used at a dilution of 
1:30,000. Mouse-anti-BIP (BD biosciences, 610978) and rabbit-anti-CRT (Abcam, 
ab2907) were used in immunoprecipitations at a concentration of 1:1000 or 1:1666 
respectively. Rabbit-anti-PDI (1:2500, Santa Cruz, sc-20132), mouse-anti-BIP (BD 
biosciences, 610978), rabbit-anti-HMGB1 (Abcam, ab18256) and rabbit-anti-GP96 
(1:1000, Cell Signaling Technologies, 2104S) were used in immunoblots.  
 
Cell culture 
All cell lines, and primary thymocytes and splenocytes were maintained in RPMI 1640 
media (Gibco) supplemented with 100 µg/ml streptomycin, 100 U/ml of penicillin (some 
media additionally contained 0.25 µg/ml of the anti-mycotic amphotericin B) and 10% 
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FBS (v/v) (Invitrogen). One exception was that during experiments in which 
immunoblotting analyses of ER proteins in the supernatants or conditioned media of 
drug-treated cells were undertaken, the samples were generated in 1% serum instead of 
10% serum to minimize background bands from serum proteins. CRT deficient (CRT
-/-
 
K42) and WT (K41) mouse embryonic fibroblasts (MEFs) were a kind gift from Dr. 
Marek Michalak. The CT26 mouse colon cancer cell line was purchased from American 
Tissue Culture Collection.  CRT deficient MEFs expressing wild type or mutant CRT or 
an expression vector with no inserted gene were generated as described (Del Cid et al., 
2010; Jeffery et al., 2011). Human multiple myeloma lines NCI H929 (H929) and 
RPMI8226 were the kind gift of Dr. Malathi Kandarpa and Andrzej Jakubowiak. Murine 
thymi from C57BL/6 or BALB/c mice were homogenized with a syringe plunger and cell 
strainer. Murine spleens were prepared as the thymi, with an additional 2-minute 
treatment with red cell lysis buffer and subsequent wash before being plated. All cells 
were maintained at 37
o
 C and 5% CO2. 
 For the generation of plasma cells, splenocytes (1.5E6 cells/ml) were cultured for 
the indicated times in RPMI 1640 supplemented with 10% FBS, penicillin, streptomycin, 
glutamine, 20 µM 2-ME, 35 ng/ml recombinant murine IL-4, at a 1:10 ratio of CD40L-
expressing Sf21 insect cells to splenocytes. 
 
Flow cytometry 
For CRT, MHC-I, and ERp57 surface analysis by flow cytometry, cell lines were 
detached with PBS + 8 mM EDTA, washed in PBS and resuspended in PBS containing 
2% FBS (flow cytometry buffer). 1.5-2x10
5
 cells were stained in 70 !l flow cytometry 
buffer containing the respective antibody. For CRT + block stains, the same dilution of 
chicken anti-CRT was pre-incubated for 15-30 minutes at room temperature with a 
saturating concentration of peptide (KEQFLDGDAWTNRWVESKHK) corresponding to 
the sequence in CRT that the antibody was generated against and affinity purified with. 
Cells were washed two times with flow cytometry buffer, resuspended in 70 !l buffer 
containing donkey anti-chicken conjugated to PE (1:250) for CRT stains, goat-anti-
rabbit-FITC (1:125) for ERp57 stains, or goat-anti-mouse-phycoerythrin (1:250) for 
MHC-I stains and incubated for 30-60 minutes rocking at 4
o
 C. Cells were then washed 
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two times. Finally, cells were resuspended in a 1x dilution of AnnV-FITC and 7AAD in 
AnnV binding buffer (10 mM HEPES (pH 7.4), 140 mM NaCl, and 2.5 mM CaCl2), and  
 Plasma cells were harvested at the indicated times. Samples were stained with 
AnnV-FITC and 7AAD as described to monitor progression through apoptosis. Parallel 
samples were stained with anti-CRT and 7AAD as described, except flow cytometry 
buffer was made with 2% rabbit serum instead of FBS, in addition to CD138-biotin, 
followed by streptavidin-APC.  
In all cases, data for each sample was collected on a FACSCanto flow cytometer 
(BD). Analysis was performed using Flowjo 8.8.6 (Treestar Inc.). 
Immunoprecipitations 
The day before drug treatment, 1-2x10
6
 cells were seeded in a 10 cm dish and allowed to 
grow overnight. The next day, the media was removed and cells were treated with 
different drugs for 5 hours as described above. Supernatants from each treatment were 
centrifuged to remove cell debris, transferred to fresh tubes, and incubated overnight with 
indicated antibodies at 4˚C, with gentle agitation. The following day, samples were 
centrifuged to remove precipitated proteins, transferred to new tubes and incubated for at 
least 5 hours with Protein G beads (GE Healthcare). The beads were washed three times 
with 1 ml of 1% NP-40 in PBS and then boiled in the presence of SDS and DTT. The 
samples were analyzed by SDS-PAGE and immunoblotting with indicated antibodies. In 
parallel, cells from each plate were harvested and lysed in triton X-100 lysis buffer (10 
mM Na2HPO4, 10 mM Tris, 130 mM NaCl, 1% Triton X-100, complete EDTA-free 
protease inhibitors, pH 7.5) on ice for at least 1 hour, followed by a 30-minute 
centrifugation at 4
o
 C to remove cell debris. Protein concentrations of cleared lysates 
were determined with Pierce bicinchoninic acid (BCA) assay and these lysates were 
included in the immunoblotting analysis of the immunoprecipitated proteins. 
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RESULTS 
Differential impacts of ER-stress inducing drugs on cell-surface CRT and MHC-I 
 
THP inhibits sarco-endoplasmic reticulum Ca
2+
-ATPase pumps and causes a 
reduction in levels of ER calcium (Thastrup et al., 1990). We recently showed that THP 
treatment of MEFs for short times (5-6 hours) induces cell-surface expression of CRT 
(Jeffery et al., 2011), as previously shown in neuroblastoma cells (Tufi et al., 2008), and 
additionally that THP treatment of the MEFs also induced CRT secretion (Jeffery et al., 
2011). In the present studies, we asked whether treatment of cells with another drug 
commonly used to induce ER stress, TUN, would also result in cell-surface and secreted 
CRT. Additionally, the effect of treating cells with the anthracyclin chemotherapeutic 
mitoxantrone (MTX) was also tested, as previous studies have suggested that MTX is a 
strong inducer of cell-surface CRT in pre-apoptotic and apoptotic cells (Obeid et al., 
2007b; Panaretakis et al., 2008a; Panaretakis et al., 2009).  
We first examined cells subject to short drug exposures, which left the large 
majority of cells intact. To distinguish the apoptotic population that had exposed PS on 
the outer leaflet of the plasma membrane (Fadok et al., 1992), annexin-V (AnnV) was 
used. Furthermore, 7-Aminoactinomycin D (7AAD) was used, which is impermeable to 
live and early apoptotic cells, but stains late-apoptotic/secondary necrotic cells that have 
lost membrane integrity. The analyses were initially conducted with fibroblasts derived 
from wild-type (WT MEFs) or CRT deficient mouse embryos (CRT
-/-
 MEFs) to control 
for the specificity of antibody binding. Untreated cells, or cells exposed to TUN, THP or 
MTX for 5-7 hours were triple stained with AnnV-FITC, chicken-anti-CRT followed by 
anti-chicken-PE, and 7AAD, and analyzed by flow cytometry. As previously shown 
(Jeffery et al., 2011), in the AnnV(-), 7AAD(-) gate (which comprised 80-90% of cells in 
all treatment groups (Fig. 2.1A)), THP treatment induced a significant enhancement in 
surface CRT relative to untreated cells (Fig. 2.1B). THP-induced increase in CRT surface 
staining of treated cells relative to untreated cells was observed in WT MEFs but not in 
CRT deficient MEFs, demonstrating specific staining for CRT (Fig. 2.1B). The THP-
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induced increase in CRT stain was also inhibited by pre-treatment of the anti-CRT 
antibody with the CRT-derived, peptide epitope (peptide block) that had been used as an 
immunogen for generating the anti-CRT antibody (anti-CRT+block), demonstrating that 
the staining was specific to the Fab region of the antibody. Consistent with a previously 
published study by Obeid et al. (Obeid et al., 2007b), TUN did not induce surface CRT 
expression in viable cells. In contrast with the same study, however, we saw little pre-
apoptotic induction of surface CRT in response to short MTX treatments relative to the 
CRT up-regulation induced by short THP treatments of cells (Fig. 2.1B).  
!"#!
Figure 2.1 A specific form of ER stress induces cell-surface CRT. 
Cell death profiles (A and C) and surface CRT expression profiles (B and D) of different 
treatment conditions were analyzed by flow cytometry. WT or CRT deficient (CRT-/-) MEFs were 
incubated in 5 µM THP (THP), 1 µM MTX (MTX), 10 µg/ml TUN (TUN), or media alone 
(UNT) for 5-7 hours (A-B) or 17 hours (C-D).  Cells were then stained with anti-CRT (anti-
CRT), anti-CRT pre-incubated with the CRT-derived peptide used as the immunogen and used to 
affinity purify the antibody (anti-CRT+block), or secondary antibody alone (control). All cells 
were also stained with AnnV and 7AAD and analyzed by flow cytometry. The median 
fluorescence values of anti-CRT staining of treated cells were measured for the AnnV(-)7AAD(-) 
(B and D as indicated) or the AnnV(+)7AAD(-) populations (D as indicated) and plotted as a 
ratio relative to the median fluorescence of AnnV(-)7AAD(-), untreated cells stained under the 
same condition (B and D). In B, inset shows representative histogram overlays of untreated 
(UNT, (fill)) or THP-treated (THP (dashed)) CT26 cells stained with anti-CRT antibody. THP-
treated cells were stained in the presence (block (line)) or absence (THP (dashed)) of the peptide 
block. (A and C) Percentage of cells in the AnnV(-)/7AAD(-) (viable/pre-apoptotic), 
AnnV(+)/7AAD(-) (early apoptotic) and AnnV(+)/7AAD(+) (late apoptotic/secondary necrotic) 
populations are shown. Graphs show averages of 5-10 (A), 5-7 (B), 3-5 (C), or 2-3 (D) 
experiments. The p-values from two-tailed, paired t-tests are indicated. 
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Because of the contrast of our data with the findings presented by Obeid et al. 
(Obeid et al., 2007b), we measured changes in surface CRT levels in the CT26 mouse 
colon cancer cell line used in that study. The strong induction of cell-surface CRT seen in 
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THP-treated WT MEFs was also seen in CT26 cells. In contrast, MTX-treatment did not 
expose surface CRT in CT26 cells, similar to the results obtained with WT MEFs  (Fig. 
2.1B). It is possible that expression of cell-surface CRT in MTX–treated cells occurs with 
different kinetics than those in THP-treated cells, or in cells that are at a different stage of 
cell death. To examine impacts of longer time-points of each drug treatment upon surface 
CRT induction, we next examined cells treated with each drug for 17 hours, which 
induced approximately 2-5 times more apoptotic cells (Fig. 2.1C). This allowed us to 
compare surface CRT levels on AnnV+ apoptotic cells and AnnV(-) pre-apoptotic cells to 
those on viable, AnnV(-), untreated cells (Fig. 2.1D). None of the long drug treatments 
induced a significant increase in CRT staining in apoptotic or pre-apoptotic MEFs 
although the MTX-treated, apoptotic cells had a trend suggesting a slight up-regulation of 
surface CRT relative to viable, untreated cells (Fig. 2.1D).  
The interpretation of some of the data presented in Figure 2.1D may be 
complicated by the fact that apoptotic cells are smaller than viable cells (Fig. 2.2A). To 
further examine this point, we compared the level of surface CRT staining in the presence 
or absence of the anti-CRT peptide block within a given viable or apoptotic cell 
population (Fig. 2.2B-C). Figures 2.2B-C include some of the same data shown in Figure 
2.1B and D, but analyzed differently as described. We also sought to further characterize 
the ability of the drug treatments to induce cell-surface CRT expression in other cell 
types. Therefore, we analyzed experiments performed with additional cell types using the 
anti-CRT/anti-CRT+block ratio (Fig. 2.2B-C & 2.3). These analysis showed similar 
trends of induction in AnnV(-) cells as measured in Figure 2.1B. Interestingly, MTX-
treated AnnV(-) cells had slightly higher levels of CRT than untreated AnnV(-) WT 
MEFs. This difference was statistically significant, and specific to the WT MEFs (Fig. 
2.2B). These data analyses also confirmed that apoptotic cells resulting from long THP 
treatments do not have elevated levels of cell surface CRT, suggesting that the 
association of CRT with the cell surface is transient or unstable (Fig. 2.2C). 
!"#!
Figure 2.2 Impacts of cell size, cell type and drug treatment on surface CRT 
expression and detection. 
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Figure 2.3 Cytotoxicity of MTX, TUN & THP on various additional cell types. 
The indicated cell lines were treated and stained as in Figure 2.1 and 2.2 with data from slightly 
altered time points averaged together in the graphs. Times of drug treatments for separate 
experiments include: C57BL/6J (B6) thymocytes 2.3, 5.3 or 6.3 hrs (n=3, average shown), and 
BALB/cJ (balbC) spleens 5.75 hrs (n=1), multiple myelomas RPMI8226 4.5 or 6 hrs (n=2) and 
H929 4.5 or 8.5 hrs (n=1). 
 
Consistent with the data analyses from Figure 2.1D, the analyses of Figure 2.2C 
suggest that apoptotic cells resulting from longer MTX treatments have elevated levels of 
CRT, although the differences did not achieve statistical significance. Overall, it appears 
that MTX-induced surface CRT is lower in AnnV(-) cells at early time points relative to 
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that induced by THP, and quite variable in AnnV(+) cells at later time points. 
Additionally, whereas THP-induced CRT surface expression was observable in WT 
MEFs and CT26 cells following short time points of drug treatment, similar treatments of 
other cell types including primary murine splenocytes, thymocytes, and other cancer cell 
lines did not strongly induce cell-surface CRT (Fig. 2.2B-C). It is possible that the cancer 
cell lines display cell surface CRT in the absence of drug treatments as recently suggested 
(Chao et al., 2010), which could account for the lower levels of THP-induced surface 
CRT (Fig. 2.2B-C). However, it should be noted that the various cell types differed in 
their susceptibility to each drug’s cytotoxicity (Fig. 2.3). Further investigations will be 
needed to understand the cell type specific effects of THP treatments on cell-surface CRT 
induction.  
To examine how the different drug treatments affect surface expression of other 
proteins, we measured surface expression of MHC class I, a protein that is constitutively 
expressed on the cell surface of most cell types under normal cellular conditions (Fig. 
2.4A-B). As previously described (Jeffery et al., 2011), short THP treatments reduced 
cell-surface MHC class I. TUN treatment also resulted in consistent decreases in cell-
surface MHC-I, whereas MTX treatment did not decrease surface MHC class I (Fig. 
2.4A-B). TUN treatment resulted in an average decrease of 36, 48 and 39% in CRT 
deficient MEFs, WT MEFs (H-2K
b
) and CT-26 cells (H-2D
d
), respectively (Fig. 2.4A-B). 
The average decrease in MHC-I in response to THP was less: 26, 39 and 18% in CRT 
deficient MEFs, WT MEFs (H-2K
b
) and CT-26 cells (H-2D
d
), respectively (Fig. 2.4A-B). 
As noted, two different MHC-I haplotypes responded with the same trend. Consistent 
with the decrease on the cell surface, both TUN and THP decreased total cellular MHC-I 
heavy chain levels in cell lysates (note that deglycosylation by TUN induces a significant 
mobility shift of the MHC-I heavy chain, indicated by *d.g.) (Fig. 2.4C). However, in 
contrast with the relative effects of the two drugs on cell surface MHC-I, THP more 
dramatically reduced levels of total cellular MHC-I heavy chains (Fig. 2.4C).  
!"#
Figure 2.4 TUN and THP, but not MTX, decrease surface and total expression of 
MHC-I. 
Flow cytometric analyses of MHC class I cell-surface expression were conducted following 
different treatments of cells. (A) WT or CRT-/- MEFs or (B) CT26 mouse tumor cells were 
treated as in Fig. 2.1A-B. Cells were then stained with indicated anti-MHC-I antibodies or 
secondary antibody alone (control). All cells were also stained with AnnV and 7AAD and 
analyzed by flow cytometry. The AnnV(-)7AAD(-) populations were analyzed in all cases. 
Graphs show averages of 3 experiments. The p-values from two-tailed, paired t-tests are 
indicated. (C) Anti-MHC-I heavy chain immunoblot of lysates from cells treated as in A-B. 
MHC-I heavy chains (*MHC-I H.C.), d.g.=deglycosylated. 
#
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Consistent with these analysis, MHC-I was recently shown to be significantly 
decreased on human thyrocytes following longer exposures to TUN or THP (Ulianich et 
al., 2011). Furthermore, MHC-I was significantly decreased on mouse cells subject to 
two different non-pharmacological ER stresses: exposure of cells to the saturated fatty 
acid palmitate, or glucose deprivation of cells (Granados et al., 2009). Thus, the ER stress 
inducing drugs differentially impact surface expression of cellular proteins. Both reduce 
surface expression of MHC class I, a constitutively secreted cell-surface protein, whereas 
only THP treatment induces the cell-surface expression of CRT at early time points post-
treatment. Based on these results, we conclude that cell surface expression of various 
proteins in the secretory pathway is differentially effected by different ER stress stimuli. 
 
Several ER resident proteins are released in THP but not TUN-treated cells  
 
We examined secretion of ER resident proteins in response to 5-hour treatments 
of WT MEFs with different drugs. Supernatants from the different drug-treated cells were 
separated by SDS-PAGE and immunoblotting analyses were performed with antibodies 
directed against gp96 and PDI. In addition, as neither CRT nor BiP were detectable by 
direct immunoblotting analyses, proteins present in supernatants were 
immunoprecipitated with antibodies against CRT and BiP, followed by immunoblotting 
analyses to detect those proteins. THP, but not TUN or MTX induced secretion of at least 
four proteins that are normally retained within the ER: CRT, gp96, PDI and BiP (Fig. 
2.5A). Although depletion of ER calcium is expected to occur almost immediately 
following THP treatment (Thastrup et al., 1990), THP-induced secretion of ER 
chaperones was not detectable at 1.25 or 2.5 hours following THP treatment (Fig. 2.5C). 
These findings suggest that ER calcium depletion alone is insufficient to induce a 
detectable loss of ER retention of chaperones. Previous studies with other cell types 
indicate that BiP (Okada et al., 2003; Winnay et al., 2010) and CRT (Llewellyn et al., 
1996; Waser et al., 1997) mRNA levels are upregulated following 2-5 hours of TUN and 
THP treatment and that BiP protein levels are increased within 5 hours of TUN treatment 
(Winnay et al., 2010). Consistent with these UPR induction kinetics, an examination of 
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changes in BiP and CRT protein levels revealed small increases in CRT and BiP 
expression at 3 hours, and stronger induction 5 hours post-TUN treatment (Fig. 2.5D). 
Over the same time-frame, THP treatment decreased the levels of cellular CRT and BiP, 
with stronger reduction seen at 5 hours compared to 3 hours (Fig. 2.5D). This is 
consistent with the observed increases in ER chaperone secretion during this time-frame 
(Fig. 2.5C). Therefore, the increase in expression of ER chaperones in response to TUN 
and THP is not sufficient to induce detectable secretion of ER chaperones. Taken 
together, these findings suggest that both depletion of ER calcium and increases in ER 
chaperone expression are required for chaperones to escape ER retention in THP-treated 
cells.  
!"#
Figure 2.5 Various ER chaperones are released from THP-treated fibroblasts  
(A) Immunoblotting of cell supernatants and lysates for the presence of various ER chaperones. 
Supernatants (CM1) from cells treated with TUN, MTX or THP or untreated cells were harvested 
in parallel with the corresponding cell lysates. Direct immunoblotting analyses of each fraction 
were performed for PDI and gp96. For CRT and BiP, proteins in cell supernatants were first 
immunoprecipitated (IP) with anti-CRT or anti-BiP, prior to immunoblotting analyses. (B) 
Kinetics of PDI and gp96 secretion. Analyses were performed as in A, but immunoblotting 
analyses were undertaken at the indicated time points. (C) Kinetics and magnitude of BiP and 
CRT induction in response to TUN & THP. Indicated microgram amounts of total cell lysates 
were analyzed as in A at the indicated time-points post-drug treatments. Representative blots of 
3-4 experiments are shown in A. Data are based on (B) 1 experiment and (C) 1 experiment 
shown, representative of 2 total experiments (A) Approximately 8500 cells per lane contributed to 
the CM1 used to blot for PDI and gp96. The blots of corresponding lysates show approximately 
30,000 cells worth of lysate. (A-C) Vertical black lines in blots indicate places where lanes of the 
blot were re-arranged to match the labeling scheme used in adjacent immunoblots or to digitally 
remove lanes containing size standard (relevant bands from size standard are shown digitally for 
each blot).  
#
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In THP-treated cells, ER chaperones follow the secretory route to gain access to the 
extracellular compartment  
 
As previously described (Rizvi et al., 2004), analysis of cell lysate-derived CRT 
by immunoblotting revealed that THP treatment of cells induced CRT glycosylation (Fig. 
2.5A, CRT blot, lane 4) in a subset of CRT molecules present in the cell. The 
glycosylation site of CRT appears to be buried under normal conditions, but becomes 
partly exposed under calcium-depleting conditions (Jeffery et al., 2011). It was of note 
that the glycosylated CRT species was absent from cell supernatants, suggesting that the 
glycosylated form of CRT was either ER retained, or preferentially retained on the cell 
surface (Fig. 2.5A) (Jeffery et al., 2011).  
Since CRT glycosylation is partial and induced by specific cellular conditions, we 
assessed the glycosylation status of gp96, a constitutively glycosylated protein, in order 
to further understand the cellular exit route for ER chaperones in THP-treated cells. A 
cytosolic route has recently been described for CRT release from apoptotic cells (Tarr et 
al., 2010). Since cytosolic localization of proteins induces their de-glycosylation, we 
assessed the glycosylation status of extracellular gp96 in order to further understand 
whether a secretory or cytosolic route was used in the trafficking of gp96 (and by 
inference, other ER proteins) to the extracellular space in THP-treated cells. Previous 
findings indicate that gp96 secreted in response to cellular calcium perturbation exits the 
cell through the secretory pathway and becomes differentially glycosylated as it travels 
through the Golgi (Booth and Koch, 1989). Consistent with these findings, gp96 from 
cell supernatants migrated more slowly than gp96 in cell lysates (Fig. 2.6A). When 
supernatants from THP-treated cells were digested with Peptide:N-Glycosidase F 
(PNGase F), which cleaves carbohydrate residues from glycoproteins, and analyzed by 
immunoblotting with an anti-gp96 antibody, a decrease in molecular weight was 
observed, indicating that secreted gp96 is indeed glycosylated (Fig. 2.6B, gp96 blot, 
lanes 8 and 9). Finally, the induction of cell-surface CRT in response to THP was 
reduced when the cells were pre-treated with brefeldin-A (BFA), which blocks ER-Golgi 
trafficking (Fig. 2.6C). Together, these findings indicate that THP treatment of cells 
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perturbs normal ER retention mechanisms, and that ER proteins exit the cell via a 
secretory route in response to THP treatment.  
 
 
 
Figure 2.6 Release of ER chaperones from THP-treated cells involves the secretory 
pathway. 
(A and B) Immunoblotting analyses with anti-gp96 of supernatants (CM1) and lysates from THP-
treated or untreated cells to analyze the presence of glycosylated forms of gp96 in cell 
supernatants following THP treatment. (A) For this immunoblot, SDS-PAGE-based protein 
separation was undertaken on an 8% polyacrylamide gel, and separation optimized compared to 
that shown in 3A, to allow for resolution of different forms of gp96. The supernatant sample 
(CM1) was also run adjacent to the lysate sample to better resolve alterations in electrophoretic 
mobility resulting from post-translational modifications. The vertical black line in the gp96 blot 
denotes lanes that were cut and pasted from the same blot. B) Indicated cell supernatant samples 
were first digested with Peptide:N-Glycosidase F (+) or left undigested (-), prior to the 
immunoblotting analyses. C) BFA blockade of the secretory pathway inhibits THP-induced 
surface CRT expression. Cells were pre-treated with BFA for 45 minutes followed by addition of 
THP for 6-7 hours. Cells were harvested and surface CRT expression was measured in the 
AnnV(-) and 7AAD(-) population by flow cytometry as described. Graph shows ratio of surface 
CRT median fluorescence of BFA+THP-treated/untreated cells. The blot shown in B is 
representative of 3 experiments and the data in C are the average of 2 experiments.  
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CRT surface expression in response to THP is independent of ERp57 co-
translocation 
                 
The data of Figure 2.5A indicate that THP-treatment does not result in a specific 
release of CRT, but rather in a generalized loss of ER retention of various ER proteins. 
This mechanism of CRT release from the ER is distinct from that suggested for 
anthracyclin-induced CRT surface expression, where the specific co-translocation of 
CRT-ERp57 complexes was indicated (Obeid, 2008; Panaretakis et al., 2008a). In the 
ER, CRT and ERp57 interact via the P-domain of CRT, and amino acid W244 within the 
P-domain of CRT is important for binding to ERp57 (Del Cid et al., 2010; Frickel et al., 
2002; Martin et al., 2006). To test the requirement for ERp57 co-translocation for CRT 
surface expression, we first measured ERp57 surface expression under the conditions that 
we detected surface CRT. A rabbit-anti-ERp57 antibody (used in the published work 
characterizing anthracyclin-induced CRT:ERp57 complex surface expression (Obeid, 
2008; Panaretakis et al., 2008b)) did not detect cell-surface ERp57 in THP-treated CT-26 
tumor cells, or in WT or CRT deficient MEFs (Fig. 2.7B). To further test the requirement 
of the CRT:ERp57 interaction for CRT surface expression in THP-treated cells, wild-type 
CRT, or CRT mutants unable to bind to ERp57 (Del Cid et al., 2010) (a W244A point 
mutant and a delta P (%P) truncation mutant lacking the P-domain) were expressed in 
CRT deficient MEFs using retroviral infections. Both mutant CRT proteins were induced 
on the cell surface in response to THP treatment at levels that correlated with their total 
expression in the lysates (Fig. 2.7B), rather than with their abilities to interact with 
ERp57 (Fig. 2.7C). Thus, CRT does not require association with ERp57 to be expressed 
on the cell surface in response to ER calcium depletion. Whether ERp57 is present in 
supernatants of THP-treated cells is unclear as ERp57 was not detectable in cell 
supernatants by immunoblotting analyses (data not shown); however ERp57 migrates in 
close proximity to background bands present in the cell supernatants, and low levels of 
secreted ERp57 may be masked by the background signals.  
!""!
Figure 2.7 THP-induced surface CRT expression is independent of CRT-ERp57 
binding.  
(A) Flow cytometric assessments of surface ERp57 expression. CT26 mouse colon cancer cells, 
WT MEFs or CRT-/- MEFs were treated with 5 µM THP for 5-7 hours, and stained with the 
indicated primary antibody (anti-CRT or anti-ERp57) and/or the respective secondary antibodies 
(control–secondary antibody alone). Anti-CRT-stained cells were additionally stained with AnnV 
and 7AAD and anti-ERp57 stained cells were stained with PI. Cells were analyzed by flow 
cytometry and the median fluorescence of treated cells relative to untreated cells is shown for the 
respective AnnV(-)7AAD(-), or PI (-) populations. The surface CRT data in (A) are the same as 
those shown in Fig. 2.1, shown again in this figure as a comparison to ERp57 surface expression 
(B) Immunoblotting analyses of lysates from CRT-/- MEFs infected with retroviruses encoding 
wild CRT (WT), a CRT construct lacking the P-domain (!P), a CRT point mutant that is unable 
to interact with ERp57 (W244A), or a virus lacking CRT (vec). (C) Flow cytometric analysis 
measuring cell-surface CRT before and after THP treatment of the MEFs described in B. 
Representative blots of 3-4 experiments are shown in B. Flow cytometric data are the averages of 
(A) 6-8 (MEFs) and 4 (CT26) experiments for anti-CRT stains and 2-4 experiments for anti-
ERp57 stains or (C) 3-5 experiments. The p-values from two-tailed, paired t-tests are indicated. 
!
  
 56 
 
 
 
  
 57 
Polypeptide-based interactions contribute to CRT binding to the cell surface of ER 
calcium-depleted fibroblasts 
 
 We next asked what types of protein:protein interactions were used by CRT to bind 
to the cell surface. As an ER chaperone, CRT binds and promotes folding of immature 
glycoproteins in the ER. CRT recognizes and binds immature glycoproteins by a single, 
terminal glucose molecule found on the carbohydrate moiety Glc1Man9GlcNAc2 
(Glc=Glucose, Man=Mannose, GlcNAc = N-Acetyl Glucosamine). The terminal glucose 
is removed from a secretory protein following its proper folding and prior to ER exit. 
Glycan-mediated binding of CRT to protein clients or co-chaperones could allow for the 
co-trafficking of protein-CRT complexes through the secretory pathway, preventing 
Golgi glycosidase access to substrate glycans. Wiest et al. suggested this model for 
surface expression of CNX in immature thymocytes, where calnexin molecules traffic to 
the thymocyte surface in complex with glycosylated CD3 molecules (Wiest et al., 1997). 
In addition to glycan-based binding, CRT displays direct polypeptide-based binding 
under ER stress conditions including calcium depletion and heat shock (Rizvi et al., 
2004). In response to ER stress, CRT also demonstrates an ability to bind and prevent 
aggregation of several non-glycosylated protein substrates in vitro (Mancino et al., 2002; 
Saito et al., 1999). Therefore, generic polypeptide binding sites of CRT could become 
relevant to CRT-protein interactions in ER-calcium-depleted cells. 
 To examine whether CRT was binding to cell-surface proteins via its glycan or 
generic polypeptide binding sites, we expressed CRT mutants with various defects in 
their protein binding abilities in CRT
-/-
 MEFs. The cell-surface expression and secretion 
of these CRT mutants was measured in the various THP-treated, CRT
-/-
 MEFs. Tested 
mutants included those with the lowest (mCRT(L139A)) or highest (mCRT(H153A)) 
polypeptide-specific chaperone activities, a glycan binding-deficient mCRT(W302A) 
mutant, and a mutant designated mCRT(VLI) mutant. The mCRT(VLI) triple mutant has 
the same L139A mutation as mCRT(L139A), but also has V138A and I140A mutations, 
resulting in lower conformational stability than mCRT(L139A) (Jeffery et al., 2011). 
Therefore, comparing mCRT(L139A) to mCRT(VLI) assessed the relative contributions 
of site specificity and conformational effects in the observed phenotypes. We found that, 
  
 58 
compared with mCRT(WT), the conformationally stable mCRT(L139A) was strongly 
impaired in its cell-surface expression after THP treatment of cells (Fig. 2.8, A and E). 
Surface expression of the triple mutant, mCRT(VLI), was significantly enhanced relative 
to mCRT(L139A). These findings indicate the conformational stability of 
mCRT(L139A), rather than a direct involvement of leucine 139 in cell-surface protein 
binding, contributes to the low cell-surface expression of mCRT(L139A) in THP-treated 
cells (Fig. 2.8, B and E). Mutant mCRT(H153A) was found at higher levels on the cell 
surface than mCRT(WT) within individual experimental comparisons undertaken (e.g., 
that shown in Fig. 2.8C), although the difference did not achieve significance when 
averaged values were compiled (Fig. 2.8E). Furthermore, mCRT(L139A) was secreted in 
response to THP, generally at higher levels than other mutants that were detected on the 
surface. This strongly implicates CRT’s polypeptide binding function in its ability to bind 
to the cell surface (Jeffery et al., 2011). 
 Proper folding and subsequent ER exit of glycoprotein clients en route to the cell 
surface normally results in removal of monoglucosylated carbohydrate moities, the 
primary protein client targeting mechanism used by CRT. However, during THP-induced 
ER stress and calcium depletion, it is possible that the normal glycoprotein folding 
checkpoints, namely UDP-glucose:glycoprotein glucosyltransferase’s (UGGT) 
recognition of an incompletely folded substrate, fail. Additionally, co-trafficking of CRT-
client complexes through the Golgi could protect monoglucosylated glycans from 
cleavage in the Golgi and result in cell-surface expression of glycoproteins containing 
monoglucosylated glycans bound by CRT. As noted above, this model was previously 
proposed for binding of the CRT homolog, calnexin, to the immature thymocyte cell 
surface (Wiest et al., 1997). It appears, however, that glycan-mediated binding is not 
relevant to CRT’s cell surface expression after ER calcium depletion, as mCRT(W302A), 
which is deficient in glycan binding (Del Cid et al., 2010), displayed cell-surface 
expression at a level similar to that of mCRT(WT) (Fig. 2.8, D and E). Together, these 
findings indicate that the cell-surface expression of mCRT in THP-treated cells is 
dependent on its polypeptide-receptive conformation (Fig. 2.8E).  
!"#!
Figure 2.8 Polypeptide-based interactions contribute to CRT binding to the cell 
surface of ER calcium-depleted fibroblasts.  
(A–D) representative histograms show THP-induced cell-surface CRT in K42 cells expressing 
mCRT(WT) or indicated mutants. Analyses were performed as described in Fig. 2.1. (E) Results 
are averaged across 2-4 independent analyses for each mutant. MFI indicates mean fluorescence 
intensity. NS indicates not significant. ** Indicates p<0.01. *** Indicates p<0.001. All p values 
were generated using a two-tailed, unpaired t test. PE=Phycoerythrin. Elise Jeffery performed 
these experiments. Figure taken from Jeffery, E., Peters, L.R., and Raghavan, M. (2011). The 
polypeptide binding conformation of calreticulin facilitates its cell-surface expression under 
conditions of endoplasmic reticulum stress. J Biol Chem 286, 2402-2415. 
!
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Surface CRT is not upregulated during plasma cell differentiation, but is elevated 
on apoptotic plasma cells, unlike other primary apoptotic cells 
 
As a model of physiological ER stress, we examined levels of cell surface CRT 
on plasma cells. Plasma cells are highly secretory and are under constitutive ER stress 
(reviewed in (Todd et al., 2008)). The UPR-activated transcription factor Xbp-1 is 
required for plasma cell differentiation (Reimold et al., 2001). Stimuli often used in vitro 
to induce plasma cell differentiation include LPS and CD40L+IL4 treatments of 
splenocytes. The spliced form of Xbp1 mRNA, which encodes the active Xbp1 protein, is 
detected following 48 hours of CD40L+IL4 treatment of splenocytes and is increased 
following 72 hours of CD40L+IL4 treatment, which correlates with maturation of plasma 
cells (Iwakoshi et al., 2003). Thus, we IL-4 treated splenocytes co-cultured with CD40L 
expressing insect cells to induce plasma cell differentiation. Plasma cells in the 
splenocytes culture were measured by the plasma-cell specific marker, CD138/syndecan-
1 (Fig. 2.9A). The percentage of plasma cells in the culture was maximal following 3 and 
4 days of stimulation at which point ~10-40% of the cells were non-apoptotic (Fig. 2.9A-
B). For technical reasons, the simultaneous AnnV stains of the CRT-stained plasma cells 
were not performed. However, upon exposing phosphatidylserine (widely used as criteria 
to classify a cell as apoptotic) cells show a significant and almost discrete shift from a 
higher FSC, higher SSC profile (annexin-V(-) and viable) to a lower FSC, lower SSC 
profile (annexin-V(+) and apoptotic). Therefore, in the absence of an AnnV stain, a cell’s 
position in a FSC/SSC plot serves as a fairly reliable indicator of whether or not a cell 
exposed phosphatidylserine. This is demonstrated in Figure 2.2. Therefore, FSC/SSC 
gating was used to infer the apoptotic status of the plasma cells in Figure 2.9. On days 3 
and 4 of stimulation, apoptotic (low FSC) but not live (high FSC) plasma cells had levels 
of surface CRT elevated 2-4 fold indicated by the CRT/block ratio (Fig. 2.9C). Thus the 
UPR experienced by live plasma cells does not interfere with ER retention of CRT to a 
degree measurable by flow cytometry, in contrast with that induced by THP-treatment of 
live fibroblasts (Figs. 2.1 & 2.9).  
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Figure 2.9 Surface CRT is upregulated on apoptotic but not live plasma cells. 
(A) Kinetics of plasma cell differentiation in splenocytes treated with IL-4 and co-incubated with 
CD40L-expressing insect cells. As suggested, the percentage of 7AAD(-), CD138(+) cells shown 
includes both live and apoptotic plasma cells. (B) Cell death profiles on days 3 and 4 of treatment 
(C) Cell-surface CRT measured as in Fig. 2.1B on live or apoptotic 7AAD(-), CD138(+) cells. 
Annexin-V was not included in these stains, so cell size and granularity was used to differentiate 
apoptotic and viable cells (as shown in Fig. 2.4A). The data represent (A) 1 and (B-C) 2 
experiments respectively. These experiments were performed in collaboration with the lab of Dr. 
Wesley Dunnick. 
 
To determine if the elevated levels of cell surface CRT seen on primary, apoptotic 
plasma cells were also present on other primary lymphocytes we measured the CRT 
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median fluorescence of apoptotic or non-apoptotic lymphocytes (Fig. 2.10A). Untreated 
thymocytes and splenocytes had ~20% or 7% ‘early’ (AnnexinV single positive) 
apoptotic cells, respectively, following culture for 6-15 hours in unsupplemented media 
(Fig. 2.10B). The observed apoptosis was likely a result of lymphocytes undergoing 
‘death by neglect.’ Further apoptosis was induced in parallel cultures treated with 
dexamethasone (Fig. 2.10B). Neither ‘death by neglect’ nor dexamethasone-induced 
apoptotic splenocytes and thymocytes had increased cell surface CRT expression (Fig. 
2.10A). Plasma cells have increased expression of CRT and other ER chaperones relative 
to unstimulated splenocytes (Skalet et al., 2005), which may explain the differences in 
cell surface CRT levels on apoptotic plasma cells versus apoptotic splenocytes and 
thymocytes.  
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Figure 2.10 Surface CRT is not found on other live or apoptotic primary 
lymphocytes. 
(A) Cell death profiles of freshly harvested thymocytes and splenocytes following 6-15 hours in 
unsupplemented media or in media containing the cytotoxic drug dexamethasone (Dex). 
Thymocytes die as a result of death by neglect in unsupplemented media. (B) Cell surface CRT 
measured in AnnV+ (apoptotic) relative to AnnV(-) (live) cells that were treated as in A. (A-B) 
Data on UNT thymocytes are the average of 3 experiments and data on UNT splenocytes and 
dex-treated splenocytes and thymocytes are based on a single experiment. 
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DISCUSSION 
 Cell-surface CRT is characterized as an important factor in inducing anti-tumor 
immune responses (Martins et al., 2011; Obeid et al., 2007b; Panaretakis et al., 2008a; 
Panaretakis et al., 2009). Anti-cancer regimens that induce an anti-tumor immune 
response are likely to be more effective than non-immunogenic regimens with similar 
cancer cell cytotoxicity (Green et al., 2009). Identifying conditions that induce cell-
surface CRT, and understanding mechanisms and functional consequences of cell-surface 
CRT expression could help design more effective anti-tumor therapies. Our findings 
indicate that THP induces transient, pre-apoptotic, cell-surface CRT exposure in some 
cell types (Figs. 2.1-2.4), yet significant decreases in cell surface MHC-I expression (Fig. 
2.4). The cell-surface CRT corresponds to a general interference with ER retention in 
response to THP; a mechanism with distinct features from both previously published 
mechanisms of increased cell-surface CRT expression on dying cells (Figs. 2.6 & 2.7). 
Furthermore, we identify a novel connection between poly-peptide-based protein binding 
by CRT and its cell surface expression in response to THP (Fig. 2.9 and (Jeffery et al., 
2011)). Finally, primary, apoptotic plasma cells, which are highly secretory and under 
constitutive ER stress, have elevated levels of apoptotic, cell-surface CRT measurable by 
flow cytometry, unlike other primary cell types examined (Fig. 2.9 & 2.10).  
 Our data indicate a secretory route for ER proteins (Fig. 2.6), as also suggested 
for the CRT-ERp57 co-translocation mechanism (Panaretakis et al., 2009). It is 
noteworthy that several of the ER resident proteins detectable in supernatants of THP-
treated cells (Fig. 2.5) are known calcium binding proteins of the ER (Coe and Michalak, 
2009). As is the case with CRT (Sonnichsen et al., 1994), ER retention of BiP, PDI and 
gp96 may in part involve calcium-dependent processes. However, calcium-depletion 
alone appears insufficient to induce secretion of the ER chaperones (Fig. 2.5C-D). 
Rather, the combined effects of KDEL receptor saturation and calcium-depletion appear 
to be the mechanism that drives secretion of the ER chaperones in THP-treated cells. 
Related to this, UPR induces expression of ER chaperones, but TUN and THP-induced 
UPR was shown not to induce expression of the KDEL receptor (Llewellyn et al., 1997). 
If KDEL receptor expression is not matched to that of the ligands it is expected to 
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retrieve following inappropriate ER escape, a constant occurrence even in unstressed 
cells (as described in chapter 1), one might expect a failure in KDEL-mediated ER 
retention. Similar mechanisms may be relevant to the extracellular localization of ER 
chaperones under physiological protein misfolding conditions, known to induce the UPR 
and alter ER calcium homeostasis.  
It is important to consider that increases in surface CRT by a magnitude 
measurable by flow cytometry were, in general, difficult to detect in apoptotic cells (Figs. 
2.1-2.4). Stronger non-specific protein binding to apoptotic cells could render a specific 
signal more difficult to detect by flow cytometry. Microscopic observations allow for 
visualization of CRT redistribution and possibly better detection of CRT upregulation on 
apoptotic cells as described in other studies (Gardai et al., 2005; Kuraishi et al., 2007; 
Park et al., 2008). Related to this, it should be noted in the case of Drosophila 
melanogaster, apoptotic cells do not upregulate cell-surface CRT (Kuraishi et al., 2007). 
Rather, the viable and apoptotic Drosophila cells examined had equal quantities of cell-
surface CRT. However, on apoptotic Drosophila cells cell-surface CRT redistributed into 
distinct puncta (Kuraishi et al., 2007), as also reported in mammalian cells (Gardai et al., 
2005). Importantly, CRT on the apoptotic Drosophila cell surface was sufficient for CRT 
to significantly increase phagocytic uptake despite absence of a measurable increase in 
the level of cell-surface CRT relative to viable cells (Kuraishi et al., 2007). It is of 
interest to further examine whether THP-induced cell-surface CRT expression is present 
in patches similar to that observed on apoptotic mammalian (Gardai et al., 2005) and 
invertebrate cells (Kuraishi et al., 2007). 
The mechanism of increased cell-surface CRT expression we describe has key 
differences from the other two published models. Tarr et al. proposed a model wherein 
CRT is co-expressed on the surface with PS, and is bound to PS (Tarr et al., 2010). In 
contrast, we see high levels of cell surface CRT on THP-treated PS(-) cells, and low 
levels, if any, on THP-treated PS(+) cells (Fig. 2.1-2.2). The other described mechanism 
for increased cell surface CRT exposure (induced by specific stimuli like anthracyclin 
chemotherapeutics) was initially identified and thoroughly characterized by Guido 
Kroemer’s group (reviewed in (Martins et al., 2010)). The THP-induced pre-apoptotic 
increase in CRT cell-surface expression we describe here is distinct in several ways from 
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anthracyclin-induced pre-apoptotic cell-surface CRT (reviewed in (Martins et al., 2010)). 
Unlike Kroemer’s published specific co-translocation of CRT:ERp57, our THP-induced 
surface CRT model: a) is independent of CRT-ERp57 binding, b) does not result in 
increases in cell-surface ERp57 expression measurable by flow cytometry (Fig. 2.7), and 
c) results in the secretion of several additional ER proteins. On the other hand, the two 
mechanisms have several key similarities: CRT travels through the secretory pathway 
and appears on the surface within hours of stimulus (Fig. 2.5) (Obeid et al., 2007b; 
Panaretakis et al., 2009); and PERK activation (Gass et al., 2008) and reactive oxygen 
species production (Hsieh et al., 2007) both result from THP treatment (within hours) and 
are required for inducing CRT:ERp57 complex surface expression (Panaretakis et al., 
2009).  
We show that plasma cells, a primary cell type undergoing physiological ER 
stress, do not have elevated levels of pre-apoptotic cell surface CRT (Fig. 2.9). This 
might be because plasma cell differentiation only activates the ATF6 and IRE1a/XBP1 
axes of the UPR, and not the PERK axis (Gass et al., 2008). These observations are 
consistent with the idea that PERK activation (or downstream signals) may be a general 
requirement for cell surface CRT expression. Relevant to this, the PERK axes of the UPR 
is thought to be activated by toxic or pathologic stimuli resulting from chronic ER stress 
to subsequently prepare the cell to undergo apoptosis (reviewed in (Todd et al., 2008)). 
Since chronic unresolved ER stress leads to PERK activation and subsequent apoptosis, 
PERK activation may occur in cultured plasma cells that are continually stimulated, 
thereby explaining the high levels cell-surface CRT measured on apoptotic plasma cells 
(Fig. 2.9).  Thus, PERK involvement in increased cell-surface CRT exposure may be part 
of the general mechanism for increased expression (and/or redistribution) of the known 
eat-me signal, CRT, on cells undergoing apoptosis. If PERK activation is involved in 
CRT exposure on apoptotic cells, it would couple a known apoptosis-inducing pathway 
with induction of a known eat-me signal. This interesting model suggests a system where 
the cell prepares to be ‘properly buried’ prior to its death. 
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CHAPTER THREE 
Impacts of extracellular calreticulin on phagocytosis and innate immunity 
SUMMARY 
The cellular response to ER stress plays an important role in cell survival and is 
increasingly recognized as a factor that modulates the immune response. Furthermore, it 
is widely published that many proteins involved in the cellular response to stress, 
particularly heat shock proteins (HPSs), also modulate the immune response. However, 
immunomodulation by HSPs is highly controversial and often described using bacterially 
expressed or over-expressed HSPs. Here we examined the immunological consequences 
of secretion of several HSPs including BiP, gp96 and CRT. We used THP treatment of 
MEFs, which depletes ER calcium, to induce cell-surface expression of CRT, and 
secretion of CRT, BiP, gp96 and PDI. We show that incubation of bone marrow-derived 
dendritic cells (BMDC) with THP-treated MEFs enhances sterile IL-6 production, and 
LPS-induced generation of IL-1!, IL-12, IL-23 and TNF-". However, extracellular CRT 
is not required for enhanced pro-inflammatory responses and the presence of the other 
secreted ER chaperones does not induce sterile production of IL-1!, IL-12, IL-23 and 
TNF-", or diminish the BMDC response to LPS. Importantly, the pattern of pro-
inflammatory cytokine induction by THP-treated cells and cell supernatants resembles 
that induced by THP itself, and indicates that other ER chaperones present in 
supernatants of THP-treated cells also do not contribute to inducing the innate immune 
response. On the other hand, we show that ER stress significantly enhances phagocytic 
uptake of THP-treated target cells by BMDC. Surface expression of CRT in viable, THP-
treated fibroblasts correlates with their enhanced phagocytic uptake by BMDC. These 
studies show that while cell surface CRT is able to promote phagocytic uptake of 
calcium-depleted cells, it is unable to modulate the innate immune response. 
Additionally, there is a strong synergy between calcium-depletion in the ER and sterile 
IL-6 as well as LPS-dependent IL-1!, IL-12, and IL-23 innate responses, findings that 
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have implications for understanding inflammatory diseases that originate in the ER. This 
chapter is published in part by:  
 
Peters, L.R., and Raghavan, M. (2011). Endoplasmic reticulum calcium depletion 
impacts chaperone secretion, innate immunity, and phagocytic uptake of cells. J Immunol 
187, 919-931. 
 
INTRODUCTION 
Among the functions attributed to cell-surface CRT (reviewed in (Gold et al., 
2010; Green et al., 2009)), several have important immunological implications. For 
example, cell-surface CRT on dead and dying tumor cells stimulates therapeutic and 
protective anti-tumor immune responses in mice (Obeid et al., 2007a; Obeid et al., 2007b; 
Panaretakis et al., 2009). CRT on the surface of apoptotic and dying tumor cells also 
functions as an eat-me signal in the phagocytosis of these cells (Gardai et al., 2005; 
Kuraishi et al., 2007; Obeid et al., 2007b); by this mechanism, CRT could promote the 
presentation of antigens derived from dying cells to T cells to induce anti-tumor 
immunity. However, other mechanisms could also account for, or contribute to, the 
immunostimulatory effects of cell-surface CRT. Purified ER chaperones such as heat 
shock protein 90 (HSP90), CRT (Hong et al., 2010) and gp96 (HSPC4) are implicated in 
the induction of co-stimulatory molecule expression and cytokine production by dendritic 
cells (reviewed in ((Henderson et al., 2010)). While it has been suggested that TLR 
ligand contamination could account for the reported immunogenicity of these and other 
soluble HSP’s, studies demonstrating immunogenicity of cell-associated HSPs, including 
HSP90 and gp96, suggest that HSPs can be immunomodulatory independently of 
microbial contaminants (Liu et al., 2003; Spisek et al., 2007; Tsan and Gao, 2009).  
ER calcium depletion, which causes ER stress, is reported to induce secretion or 
cell surface expression of some endogenously expressed HSPs (Booth and Koch, 1989). 
Additionally, we identified ER calcium depletion as a strong inducer of pre-apoptotic 
cell-surface CRT expression (Jeffery et al., 2011; Peters and Raghavan, 2011a). Recently, 
several papers identified interesting connections between ER stress (including ER 
calcium depletion-induced ER stress) and innate immunity (Goodall et al., 2010; 
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Martinon et al., 2010; Smith et al., 2008; Zhang et al., 2006). In particular, ER stress 
induction in macrophages caused them to produce higher levels of pro-inflammatory 
cytokines in response to several innate stimuli (Smith et al., 2008). It is possible that cell-
surface CRT expression and/or HSP-secretion in response to ER stress were involved in 
the enhanced these inflammatory responses. 
Martinon et al., subsequently showed that the transcription factor XBP-1, which is 
important in orchestrating the ER stress response, was activated by Toll-Like Receptor 
(TLR) ligation (Martinon et al., 2010). Yet, the two other arms of the UPR were absent or 
suppressed. XBP-1 was required for wild-type levels of pro-inflammatory cytokines in 
response to TLR ligation or infection (Martinon et al., 2010). Together, these results 
suggest that XBP-1 plays alternative roles in promoting innate immune responses and 
UPR. Other studies have linked inflammation with UPR induction or ER calcium 
depletion. For example, atherosclerosis (Li et al., 2004; Li et al., 2005) and familial 
dementia (Davies et al., 2009) have been associated different forms of ER stress. A 
specific inherited mutant of the protein neuroserpin that is associated with familial 
dementia, was recently shown to induce ER calcium depletion in the absence of a 
traditional UPR. Inflammation is important in the pathogensis of atherosclerosis (Li et al., 
2005) and speculated to be involved in the development of dementia (Leonard, 2007). 
Consequently it is of interest to characterize inflammatory responses to different forms of 
ER stress and the role of extracellular chaperones.  
In the present chapter, we examined the innate immunological consequences of 
cell-surface CRT using THP-treated wild-type and CRT
-/-
 MEFs, which have impaired 
ER retention (Fig. 2.5) and increased cell-surface CRT expression (Fig. 2.1 (Jeffery et 
al., 2011)). THP-induced secretion of various extracellular chaperones, including CRT, 
BiP, gp96 and PDI (Fig. 2.5), also allowed us to examine abilities of the soluble, 
extracellular forms of these ER chaperones to modulate the innate immune response. We 
found that incubation of BMDC with THP-treated fibroblasts or conditioned media from 
the treated cells enhances production of IL-6 under sterile conditions, but not IL-1!, IL-
12 or TNF-", cytokines previously shown to be induced by macrophages following 
exposure to extracellular gp96 (Liu et al., 2003) or a CRT fragment (Hong et al., 2010). 
We also found that ER stress induced phagocytic uptake of cells by BMDC. Furthermore, 
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phagocytosis of THP-treated cells by BMDC was significantly enhanced in a CRT-
dependent manner. Finally, direct THP treatment of BMDCs enhanced IL-6 production 
under sterile conditions as previously shown in macrophages (Bost and Mason, 1995), 
and enhanced various pro-inflammatory responses to LPS more significantly than did 
BMDC treatment with TUN. Together the findings point to strong synergies between ER 
calcium depletion and innate immune responses and suggest that the combined presence 
of several ER chaperones in the extracellular environment per se is not strongly pro-
inflammatory. 
MATERIALS AND METHODS 
Generation of BMDC 
C57BL6 femurs & tibias were flushed with media and cultured in 24 well plates (roughly 
2*24 well plates per mouse). Bone marrow cells were cultured for 5-7 days in BMDC 
media: RPMI 1640 supplemented with 100 mg/ml streptomycin, 100 U/ml of penicillin, 
10% FBS (v/v), 1 mM HEPES, 1 mM sodium pyruvate, 0.1 mM MEM Non-Essential 
Amino Acids (Life Technologies), GMCSF (conditioned media diluted 1:5000) and 50 
mM 2-ME. BMDC media were changed every other day, and non-adherent and loosely 
adherent cells were harvested by pipetting. Phenotype of generated cells was examined 
by measuring upregulation of CD80/86 and MHC-II on the surface of CD11c+ cells from 
LPS-treated cultures of bone marrow derived cultures. These analyses confirmed that the 
generation protocol stimulated the differentiation of the bone marrow cells into DC (data 
not shown). 
Cytokine profiling of BMDC and generation of MEF CM 
For data in Figure 3.1, MEFs were drug-treated as indicated for 5-6 hours (Fig. 3.1) or 
20.5 hours (Fig. 3.2). Next, cells were harvested, washed 2-3 times (first in 25 ml media, 
then either twice in 10 ml or once in 25-40 ml media) and incubated alone or with BMDC 
as described below. For data shown in Figure 3.3, MEFs were treated with indicated 
drugs for 5-6 hours, supernatants collected (CM1), cells washed 3 times in 7 ml of PBS, 
following which 4 ml of BMDC media were added to the cells. After a 5-6 hour 
collection period, conditioned media, called conditioned media 2 (CM2), were harvested. 
CM1 and CM2 were centrifuged to clear any floating cells or cellular debris. For Figure 
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3.3, a portion of CM2 was added to BMDC (MEF CM2+DC) and another portion 
directly tested for the presence of specific cytokines (MEF CM2). For Figure 3.6, CM1 or 
CM2 were added directly to BMDC as in Figure 3.3.  
For Figure 3.7 CM1 and CM2 were first dialyzed using 3 kDa or 10 kDa centricon filters 
as indicated (using at least 3 successive concentrations and dilutions), before adding 
retentate or flow-through to BMDC. Separate wells of dendritic cells were directly 
treated with the indicated concentrations of the described drugs (Direct treatment), or left 
untreated. In parallel analyses, a second set of MEF plates were treated as described 
above for generation of the CM2. MEFs were then harvested and stained with AnnV and 
7AAD (to measure cell viability at the end of the MEF CM2 collection).  
Protocols for BMDC incubations with treated cells, CM or drug were adapted 
from Torchinsky et al. 2009 (Torchinsky et al., 2009). Day 5 or 6 BMDCs (5x10
5
) were 
mixed with 1x10
6
 washed target cells, co-sedimented and incubated for 19-23.5 hours 
(Fig. 3.1), 18.5 hours (Fig. 3.2) or treated separately with drugs for 21-23 hours (Fig. 3.6) 
or with MEF CM for 15-23 hours (Fig. 3.3-3.6) in 24 well plates in the presence or 
absence of described amounts of LPS before centrifuging the plates for 5 min at 241*g  
and harvesting the resulting supernatants. Supernatants were finally submitted to the 
University of Michigan Cancer Center Immunology Core (UMCCIC) for cytokine 
measurements by ELISA. Duoset ELISA development systems were purchased from 
R&D systems (Minneapolis, MN). 
 
ATP measurements 
ATP was measured as directed using the ENLITEN
®
 ATP Assay System 
Bioluminescence Detection kit (Promega). MEF CM1 and CM2 were prepared using 
opti-MEM I Reduced Serum Media (Invitrogen) as published (Selzner et al., 2004), or 
DC media as is used in the cytokine assays. We mixed 50 µL of CM with 50 µL of the 
provided recombinant luciferase in 96 well plates and used a Biotek Synergy HT plate 
reader to measure the luminescences of the samples. Relative luminescence units were 
converted to mass ATP using an ATP standard curve performed with the provided ATP 
standard. Controls include the respective media that was never added to cells (media), or 
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THP-CM2 that was pre-mixed with 10-20 U/ml of apyrase and incubated at room 
temperature for 20-40 minutes before measuring its ATP levels as described. 
 
Assays measuring phagocytosis of MEFs 
Target cells were labeled with CellTracker™ Green CMFDA (5-chloromethylfluorescein 
diacetate) (Invitrogen) in 10 cm plates that were seeded with 2-2.5x10
6
 target MEFs per 
plate 12-20 hours before labeling. Each plate was labeled as directed with 0.1-0.35 µM 
CMFDA diluted in optimem serum free media for 20-40 minutes at 37
o
 C. Media was 
removed and replaced with previously described tissue culture media (RPMI with 10% 
serum) and incubated at 37
o
 C for 30-60 minutes. After this, the media was replaced with 
media, respective plates were then exposed to 3 minutes of UV light on a UV light box or 
left untreated and plates were incubated overnight in tissue culture incubator. The 
respective plates were then treated with 5 µM THP or 10 µg/ml TUN for 5-6 hours or left 
untreated. Cells were finally harvested (UV) or washed twice in 10-12 ml PBS (untreated 
and drug-treated), then harvested with 8 mM EDTA in PBS and diluted in RPMI for 
counting (a third wash) before pelleting and resuspending at the appropriate 
concentration. 1x10
5
 Day 5 or 6 BMDC were then mixed with 4x10
5
 targets in 96 well 
plates and the plates were then incubated at 37
o
 C or 4
o
 C for 60 minutes. Cells were then 
fixed for 10 minutes with formalin (fisher PROTOCOL) diluted 1:10 in flow cytometry 
buffer (PBS+2% FBS), washed twice, stained with anti-CD11c-APC (1:220, BD-
Biosciences) for 20-40 minutes at 4
 o
 C. Cells were washed twice and data for each 
sample was collected on the FACS Canto flow cytometer (BD). Analysis was performed 
using Flowjo 8.8.6 (Treestar Inc.). CMFDA was read on the FITC channel. 
 
RESULTS 
In a CRT-independent manner, THP-treated cells, cell supernatants and THP itself 
induce and enhance innate immune responses more broadly and significantly than 
corresponding TUN treatments 
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Using THP-treated WT or CRT
-/-
 MEFs, we investigated whether cell surface 
and/or extracellular soluble CRT were linked to enhanced pro-inflammatory cytokine 
production. We first examined production of IL-6, a cytokine previously shown to be 
induced by direct treatments of murine macrophages with THP (Bost and Mason, 1995) 
or TUN (Martinon et al., 2010). WT or CRT deficient MEFs were treated with TUN, 
MTX & THP for short (5-6.5 hr) or long (20.5 hr) times as described in Chapter 2 
Materials and Methods, harvested, washed extensively with PBS, co-incubated with 
BMDC or alone, and then the cytokines in the supernatants of these cultures were 
quantified by ELISA. BMDC co-incubations with MEFs treated with THP resulted in 
higher levels of sterile/spontaneous IL-6 compared to BMDC co-incubations with other 
target cells (Fig. 3.1A). However, these effects were independent of CRT expression, as 
shown by similar levels of IL-6 resulting from BMDC co-incubations with THP-treated 
CRT-/- or WT MEFs (Fig. 3.1A). THP-induced increase in IL-6 production was also seen 
with MEFs subjected to longer time points of drug treatments (Fig. 3.2B), although the 
levels of IL-6 measured were lower (Fig. 3.1A compared to Fig. 3.2B). These findings 
are consistent with higher levels of MEF apoptosis following long drug treatments (Fig. 
3.2A compared to Fig. 2.1A), and the expected immunosuppressive effects of apoptotic 
cells (Voll et al., 1997). It is noteworthy that MTX-treated, pre-apoptotic (Fig. 3.1) or 
apoptotic (Fig. 3.2) cells did not induce significant pro-inflammatory cytokine production 
by BMDC, despite being reported to induce strong anti-tumor immune responses in mice 
(Obeid et al., 2007b). 
!"#
Figure 3.1 Co-culture of THP-treated pre-apoptotic target cells with BMDC induces 
and enhances pro-inflammatory cytokine production in a CRT-independent 
manner. 
(A-E) Cytokine production by DCs, MEFs, and DC+MEF co-cultures. WT or CRT-/- MEF target 
cells were treated with TUN, MTX or THP for 5.5 or 6.5 hours or left untreated. Adherent target 
cells were then harvested, washed and incubated in media alone (MEF alone) or co-incubated 
with BMDC (MEF+DC) in the absence (described as ‘sterile’) (A) or presence (B-E) of 0.5-2 
ng/ml LPS for 18.5-23.5 hours and the concentrations of the indicated cytokine were measured in 
duplicate by ELISA. Wells of DC incubated in the presence (B-E) or absence (A) of LPS were 
included in each experiment as an additional control (DC alone). The THP(-)LPS bars indicate 
conditions where THP-treated WT MEF or CRT-/- MEFs were incubated with DC, but in the 
absence of LPS, to illustrate the LPS dependence of enhanced production of indicated cytokines. 
The data from co-incubations of DC and MEFs show the mean and standard error of 3 (WT) or 5 
(CRT-/-) experiments. The data from MEFs alone or DC alone show the mean and standard error 
of 1-3 experiments in the presence of LPS, or 2-4 experiments in the absence of LPS. The p-
values from two-tailed, paired t-tests are indicated. 
#
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Figure 3.2 Co-culture of THP-treated, apoptotic target cells with BMDC induces 
and enhances pro-inflammatory cytokine production but to a lesser extent than that 
seen with pre-apoptotic THP-treated cells. 
(A-D) WT MEFs were treated with indicated drugs for 20.5 hours, prepared and co-cultured with 
BMDC as described for Fig. 3.1, with or without 0.5 ng/ml LPS (as indicated) for 18.5 hours. (A) 
An aliquot of treated MEFs were stained with AnnV and 7AAD to measure their viability. (B-D) 
IL-6, IL-23 and IL-1" in the co-cultures’ supernatants were measured in duplicate by ELISA. 
Data shown are from one experiment and are representative of 1-2 experiments for each analyte. 
 
  
 78 
 
 
We also examined the effect of THP-treated MEFs on production of IL-12, IL-1!, 
and TNF-", cytokines that were previously shown to be induced by a membrane-linked 
extracellular form of gp96 (Liu et al., 2003) or a bacterially-expressed CRT fragment 
(Hong et al., 2010). Additionally, we compared induction of IL-23, as both THP and 
TUN were recently reported to enhance expression of this cytokine in the presence of 
TLR agonists (Goodall et al., 2010). Co-incubating THP-treated MEFs with BMDCs 
strongly enhanced TLR-dependent (0.5-2 ng/ml LPS) production of IL-1!, IL-12p70 and 
IL-23 compared to co-incubating other drug-treated or untreated MEFs with BMDC (Fig. 
3.1B-E). CRT was not required for enhanced cytokine production in response to THP-
treated cells, and in fact, CRT-deficiency in the THP-treated MEFs appeared to correlate 
with higher levels of cytokine production. However, observed differences between wild 
type and CRT-deficient cells were not statistically significant (Fig. 3.1B-D). Compared to 
other drug treatments, THP-treated cells subjected to long (20.5 hours) drug treatments 
also stimulated IL-1! and IL-23  (Fig. 3.2C-D), although at reduced levels compared to 
co-incubations with MEFs subjected to short drug treatments (Fig. 3.1). 
Immunostimulatory effects of TUN-treated apoptotic cells upon IL-23 production were 
also measurable following longer drug treatments, but at reduced levels compared to 
THP-treated cells (Fig. 3.2C). 
  
To better understand the molecular basis for the immunostimulatory effects of 
THP-treated cells (Fig. 3.1-3.2), we next examined the impacts of conditioned media 
(CM) from various drug-treated cells (Fig. 3.3) on induction or enhancement of pro-
inflammatory cytokine production. We were particularly interested in asking whether 
secreted ER chaperones present in supernatants of THP-treated cells or residual THP 
itself might be responsible for the observed pro-inflammatory effects of THP-treated 
cells. For these analyses, following each drug treatment of 5-6.5 hours, media containing 
drugs (CM1) were removed, and cells were washed three times with at least 7 ml PBS to 
remove soluble drug present in the media. Following these wash steps, fresh media were 
collected from the washed cells over a 5-6 hour period to generate different MEF CM 
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(CM2). We noted that secretion of PDI and gp96 was detectable for several hours 
following THP removal from target cells, although at significantly reduced levels 
compared to those detected during drug treatment (Fig. 3.4, CM1 compared to CM2). 
Nonetheless, THP CM2 was able to induce pro-inflammatory cytokine production by 
BMDC with patterns resembling those induced by co-incubation of BMDC with THP-
treated cells (Fig. 3.1 and 3.3). Only trace amounts of cytokines, if any, were directly 
detectable in CM2 from various drug-treated, washed MEFs (Fig. 3.3). BMDC mixed 
with THP CM2, but not BMDC co-incubated with other CM2, produced IL-6 under 
sterile conditions (Fig. 3.3). Additionally, LPS-dependent production of IL-12p70, IL-23 
and IL-1! strongly synergized with stimulation by THP CM2 to yield more IL-1!, IL-
12p70, and IL-23 than other BMDC treatments (Fig. 3.3). However, BMDC cytokine 
production in response to THP CM2 was clearly independent of CRT expression in 
MEFs (Fig. 3.3). 
!"#
Figure 3.3 Differential induction of pro-inflammatory cytokines by conditioned 
media (CM) from drug-treated MEFs. 
BMDC were treated with MEF CM or drugs either under sterile conditions (top panel for IL-6 
measurements) or in the presence of 1 ng/ml LPS (lower panels for IL-1!, IL-23 and IL-12p70 
measurements) for 21-23 hours. The concentrations of the indicated cytokines were then 
measured by ELISA. Concentrations of the indicated cytokines in MEF CM2+DC co-incubations, 
or DC alone were measured in duplicate by ELISA. The THP(-)LPS bars indicate conditions 
where CM2 from THP-treated WT or CRT-/- MEFs were incubated with DC. CRT-/- MEF CM2 
and WT MEF CM2 bars indicate direct cytokine measurements of the indicated CM2 samples 
without further treatment with LPS. The results with WT MEFs show the average of three 
independent experiments, and the results with the CRT-/- MEFs are from a single experiment.  
#
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Figure 3.4 THP-induced secretion of ER chaperones continues at reduced levels for 
several hours following drug removal. 
Gp96 and PDI secretion by untreated or THP-treated cells over the 5 hour drug treatment period 
(CM1) and at indicated time points following removal of drug via washing of cells (CM2). Cell 
lysates are shown to mark migration positions of gp96 and PDI. 
 
 
 
 
 
The different drug-treated, washed cells used to generate CM2 were also 
harvested and stained with AnnV and 7AAD and analyzed by flow cytometry. These 
analyses indicated that, compared to other treatments, the THP CM2 generation protocol 
did not enhance levels of apoptotic/secondary necrotic cells (Fig. 3.5A). Consistent with 
these measurements of cell death, HMGB1 was not released from TUN or THP-treated 
cells used to generate CM2 (Fig. 3.5B). Moreover, there was no apparent correlation 
between the level of secondary necrotic cells in a given treatment group and its ability to 
stimulate the BMDC (Fig. 3.5A and 3.3). Therefore, necrosis-related factors were not a 
likely explanation for the immunostimulatory properties of THP-treated cell supernatants.  
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Figure 3.5 Cell viability and ATP and HMGB-1 secretion by drug-treated MEFs 
(A) Cell viability: Following collection of CM2 as described in Figure 3.3, cells were harvested 
and stained with AnnV and 7AAD to measure cell viability. (B) WT MEF CM2 and lysates from 
cells subjected to the indicated treatments were immunoblotted for HMGB1. (C-D) The ATP 
concentrations of indicated CM from WT MEFs prepared as in (A) (or in (C) using using opti-
MEM low serum media instead of DC media) were measured with the ENLITEN® ATP Assay 
System Bioluminescence Detection kit (Promega). The control (THP+APY) was THP WT MEF 
CM that was apyrase-treated prior to measuring ATP levels. 
 
 
 
Because we detected enhanced IL-1! production in the presence of LPS and THP 
CM2, and ATP is implicated as an important alarmin/DAMP (Ogura et al., 2006) for 
activating the NALP-3 inflammasome leading to IL-1! production (Mariathasan et al., 
2006), we examined the ATP concentrations in the various CM2 used to stimulate the 
BMDC (Fig. 3.5 C-D). Although ATP levels in the CM2 of THP-treated cells were not 
significantly enhanced relative to those in any of the other treatment groups, they were 
elevated above background levels in the CM2 of all treatment groups (Fig. 3.5 C-D). 
These findings suggest that extracellular ATP in the THP CM2 is not the primary 
stimulus responsible for enhanced IL-1! production in the presence of LPS. 
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It is noteworthy that IL-12p70, IL-23, IL-1! and TNF-" were not significantly 
induced by THP CM2 or THP-treated cells under sterile conditions (Fig. 3.1B-D, Fig. 
3.3, THP(-)LPS bars). In contrast, IL-12p40 and IL-1! were both previously reported to 
be induced under sterile conditions by a membrane-linked form of gp96 (Liu et al., 
2003). Furthermore, a recombinant, N-terminally truncated CRT fragment purified from 
E. coli induced TNF-" production by mouse peritoneal macrophages and human PBMC 
in the absence of a TLR agonist (Hong et al., 2010). However, TNF-" was also not 
induced by THP CM2 or THP-treated cells (wild type or CRT-deficient) under sterile 
conditions (data not shown and Fig. 3.1E). THP CM2 did moderately enhance TNF-" 
production mediated by LPS but it was independent of CRT expression by the target cells 
(data not shown). Thus, despite containing various extracellular ER chaperones, THP-
treated cell supernatants and cells induced only the production of IL-6 under sterile 
conditions, and therefore were not as broadly immunostimulatory as predicted by the 
presence of extracellular gp96 or CRT (Hong et al., 2010; Liu et al., 2003).   
Previous studies have shown that treatment of cells with TUN or THP stimulates 
activation of NF-#B in HeLa cells (Pahl and Baeuerle, 1995), production of reactive 
oxygen species (ROS) in MEFs (Hsieh et al., 2007), and significantly enhanced 
production of type I IFN, TNF-" (Smith et al., 2008), ISG15 and IL-6 (Martinon et al., 
2010) by LPS-treated macrophages. Furthermore, THP and TUN were both shown to 
enhance IL-23 but not IL-12 production by human monocyte-derived DC in response to a 
mixture of LPS and a TLR-8 agonist (CL-097) (Goodall et al., 2010). We asked whether 
direct addition of TUN or THP to murine BMDC could stimulate production of any of 
the cytokines measured in Figures 3.1, and 3.3. The levels of cytokines resulting from 
drug treatment of BMDC and CM treatments of BMDC were compared within the same 
experiment (Fig. 3.6). THP and TUN treatment of BMDC both stimulated production of 
IL-6 in the absence of LPS, although THP stimulated on average ~9.8-fold more IL-6 
than TUN at the drug concentrations and time points used in the analyses (Fig. 3.6, 9.8 
fold was the average enhancement from five experiments, of which four are shown). THP 
and TUN treatments of BMDC stimulated production of IL-1! and IL-23 (Fig. 3.6) in 
response to 1-10 ng/ml LPS. However, under the conditions tested, THP was a stronger 
inducer of IL-1!. As noted previously with human monocyte-derived DC (Goodall et al., 
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2010), lower concentrations of THP resulted in higher levels of IL-23 compared to higher 
concentrations of THP.  
!"#!
Figure 3.6 Differential induction of pro-inflammatory cytokines by different types of 
pharmacological ER stress 
BMDC were treated with MEF CM or drugs either under sterile conditions (top panel for IL-6 
measurements) or in the presence of 1-10 ug/ml LPS (lower panels for IL-1!, IL-23 and IL-12p70 
measurements) for 15-22 hours. Indicated cytokine measurements followed CM+DC, drug+DC 
or DC-media (DC alone) co-incubations in the presence or absence of LPS. THP 200 nM CM 
represents CM prepared as other CM, but by incubating MEFs with 200 nM THP instead of 5 µM 
THP. Direct DC treatment represents cytokine production by BMDC that were directly treated 
with THP (black bars), or TUN (vertically striped bars) at their specified concentrations or left 
untreated (horizontally striped bars). The (-)LPS bars represent measurements from DC treated 
with THP CM1 or 5 µM THP as indicated, but in the absence of LPS. Data are averages of four 
experiments with the exception of CM1 stimulated cytokines, which was from a single 
experiment.  
!
  
 87 
 
  
 88 
 
 
In contrast to the previous studies with human myeloid DCs, THP (but not TUN) 
treatment also enhanced IL-12p70 production in response to LPS (Fig. 3.6). However, as 
mentioned, a TLR-8 agonist was present in the studies with the human DCs, and the 
signaling cascade activated by TLR-8 may interfere with the signals leading to IL-12p70 
production in the presence of LPS and THP. It has been previously described that IL-12 
secretion requires N-linked glycosylation of the p35 subunit’s signal sequence (Murphy 
et al., 2000). Therefore, it is possible that TUN treatment of LPS-stimulated BMDC 
would lead to IL-12 secretion but it is not detected because of TUN-mediated inhibition 
of protein glycosylation. Altogether, these results suggest that the stimulation induced by 
TUN and THP is qualitatively similar, although THP more strongly induces IL-6 and IL-
1! (Fig. 3.6). 
Importantly, the patterns of cytokine induction by THP-treated cell supernatants were 
strikingly similar to those induced by direct THP treatment of BMDC (Fig. 3.6). As 
noted above, in generating THP CM2 for Figure 3.3, THP was removed from the MEFs, 
and MEFs were washed sufficiently to reduce the extracellular, soluble drug 
concentration to < 15 pM, prior to collection of CM2. However, it is possible that THP 
was sequestered within cell membranes or intracellularly and subsequently partitioned 
into the media. In support of this possibility, we found that when CM1 (cell supernatants 
from drug-treated cells) and CM2 (cell supernatants from drug-treated, washed cells) 
were extensively dialyzed in centricons (3 KDa or 10 KDa) to remove free soluble drug 
that was present, the majority of cytokine-inducing activity was present in the retentates 
rather than in the flow through, even though THP has a molecular weight of 650 Da (Fig. 
3.7). Based on these findings, it is likely that the activity of THP-treated cell supernatants 
(CM1 and CM2) (Figs. 3.3 and 3.7) and their resemblance to direct THP treatment of 
BMDC (Fig. 3.6) result from sequestration of THP within cell membranes or 
intracellularly during drug treatment of MEFs, and subsequent partitioning of active drug 
from MEFs into the CM within higher molecular weight membrane vesicles or protein 
complexes. This would allow THP to directly stimulate BMDC. THP is hydrophobic and 
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requires organic solvents (such as DMSO) for its solubilization, and thus its partitioning 
into membranes is perhaps not unexpected.  
 
Figure 3.7 Extensive dialysis of THP CM1 and CM2 does not change inflammatory 
profile induced by THP CM. 
These alternate conditions were performed in parallel with experiments described in Figure 3.6, 
except that the indicated CM were first dialyzed with either a 3 kDa or 10 kDa centricon to 
remove any residual drug monomers (THP has a molecular mass of 650 Da). Samples were 
concentrated and diluted at least 3 successive times while remaining at 4oC. Cytokines induced by 
both the retentate and flow-through were measured as indicated. 
 
 
If residual drug in THP-treated cells was responsible for the BMDC stimulating 
activity, we expected that reducing the concentration of THP used to treat MEFs during 
the CM generation would reduce the immunostimulatory capacity of THP-treated cells. 
Thus, we compared abilities of 5 µM or 200 nM THP CM1 and CM2 to induce 
production of various pro-inflammatory cytokines (Fig. 3.6). Cells treated with 200 nM 
or 5 µM THP secreted similar levels of gp96 and PDI and showed similar elevations of 
surface CRT expression (Fig. 3.8). Whereas treatments of BMDC with 5 µM THP CM1 
or CM2 induced IL-6 production, treatments of BMDC with 200 nM THP CM1 or CM2 
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did not induce sterile IL-6 production (Fig. 3.6). Furthermore, reduced levels of LPS-
induced IL-1! and IL-23 (Fig. 3.6) were observed when the 200 nM THP CM1 or CM2 
were compared to the 5 µM THP CM1 or CM2. As noted, levels of chaperone secretion 
were very similar in 200 nM and 5 µM THP CM1 (Fig. 3.8).  
 
Figure 3.8 Dose response of compromised ER retention in WT MEFs exposed to 
THP 
(A) Cell surface CRT as induced and measured in Figure 2.1B, with indicated variations in THP 
concentration. (B) Comparisons of PDI & gp96 release in response to low or high THP dose (200 
nM or 5 µM) measured as in Figure 2.6. (A) and (B) are representative of 1 and 2 experiments 
respectively. 
 
Together, these findings indicate that production of pro-inflammatory cytokines 
induced by THP-treated cells or CM was not enhanced by CRT expression by target cells 
(Fig. 3.1 and 3.3). Notably, the profiles of pro-inflammatory cytokine induction by THP-
treated cells and dialyzed CM closely resembled those induced by THP itself, suggesting 
that residual THP within protein/lipid complexes was responsible for enhanced cytokine 
  
 91 
production (Fig. 3.3, 3.6 & 3.7). Significantly, the effects of direct BMDC treatments 
with THP were qualitatively similar, but more strongly pro-inflammatory than those 
induced by TUN. 
 
CRT expression enhances phagocytic clearance of THP-treated cells, but not of 
TUN or UV-treated cells 
Because cell-surface CRT is an eat-me signal in the context of apoptotic cells (Gardai et 
al., 2005), pre-apoptotic tumor cells (Obeid et al., 2007b), and live tumor cells subject to 
CD47 blockade (Chao et al., 2010) we asked if THP-treated cells would also be 
phagocytosed in a CRT-dependent manner. A previously published flow-cytometry-
based assay (Obeid et al., 2007b) was used to measure phagocytosis. WT or CRT 
deficient MEFs were labeled with a fluorophore, then drug or UV-treated, washed and 
incubated with BMDC. The co-cultures were then fixed and stained with an antibody 
specific for the DC-specific marker CD11c. The percentage of CD11c+ events that were 
also positive for the target-cell marker were recorded as a measure of target-cell:DC 
association. The ratio of DC:target cell association in co-cultures incubated at 37
o
 C 
relative to that of co-cultures incubated at 4
o
 C is reported as the phagocytic index (the 37 
°C readings quantify adhesion and phagocytosis, whereas the 4 °C readings quantify 
adhesion alone). Uptake of UV-treated MEFs was significantly greater than untreated 
MEFs, but was independent of CRT expression by the MEFs (Fig. 3.9A). The latter 
finding was surprising in light of a previously suggested role for CRT in the phagocytic 
uptake of apoptotic UV-treated fibroblasts using fibroblasts, a macrophage cell line or 
peritoneal macrophages as the phagocytes (Gardai et al., 2005). Therefore surface CRT 
expression was tested in the UV-treated fibroblasts, which were triple stained for CRT as 
well as markers of apoptosis and plasma membrane integrity, as defined in the analyses 
of Figure 2.1. Our analyses indicated that CRT is not present or significantly induced on 
the surface of AnnV+PI- (Fig. 3.9B) or AnnV-PI- (data not shown) MEFs in response to 
UV treatment to a degree measurable by flow cytometry, consistent with the absence of 
significant, CRT-dependent uptake of UV-treated cells. Several differences in protocol 
may explain these discrepancies. These include the use of a different phagocyte (BMDC 
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(Fig. 3.9) rather than macrophages or fibroblast (Gardai et al., 2005)), a different 
phagocytosis assay (flow cytometry (Fig. 3.9) rather than microcopy (Gardai et al., 
2005)), and the use of both adherent and non-adherent UV-treated target cells (Fig. 3.9), 
rather than non-adherent UV-treated target cells (Gardai et al., 2005). Additionally, 
expression of CD91 (the proposed CRT receptor on macrophages used for clearing 
apoptotic targets) on the BMDC surface may be lower than that on macrophages. 
Differential expression of CD91 may also explain the discrepancy between the results of 
Gardai et al. with macrophages as phagocytes and our results with BMDCs as 
phagocytes. If this were the case, THP-treated target cells would presumably have to 
increase CD91 expression on the BMDC to observe the CRT-dependent uptake of THP-
treated cells. 
!"#
Figure 3.9 CRT enhances phagocytic uptake of THP-treated target cells, but not of 
UV or TUN-treated target cells.  
Cell Tracker Green (5-chloromethylfluorescein diacetate; CMFDA) labeling of MEFs, cell death 
profiles, phagocytic uptake, and surface CRT expression following different treatments. WT or 
CRT-/- MEFs were labeled with Cell Tracker Green, exposed to UV light for 3 minutes and then 
cultured for an additional 16-24 hrs, or exposed to THP or TUN for 5-6 hours, or left untreated. 
(A) Phagocytic uptake: Labeled and treated cells were washed 3 times, mixed with BMDC at an 
effector to target ratio of 1:5, and incubated for 1 hour at 37o C or 4 o C. Co-cultures were fixed, 
stained with anti-CD11c and analyzed by flow cytometry. For each cell type and treatment 
condition, the percentages of CMFDA+ events in the CD11c+ gate were measured for the 4 oC 
and 37 oC plates, and phagocytic index is plotted as the 37 °C/4 °C ratio of those percentages. 
The phagocytic index data are averages of 8 total experiments for all conditions with the 
exception of TUN, which shows the average of four experiments. On average 3-6% of the total 
added target cells were phagocytosed (B) Surface CRT expression was measured in UV-treated 
WT & CRT-/- MEFs as described in Fig. 2.1, and data are representative of 3 experiments. (C) 
Cell death profiles of target cells: CMFDA-labeled MEFs subject to indicated treatments were 
stained with AnnV-PE and 7AAD to quantify the percentages of MEFs in the indicated 
populations. Graphs show the averages of 6 experiments for all conditions except TUN 
treatments, which show the average of 3 experiments. AnnV/7AAD data were not collected in 2/8 
experiments. (D) CMFDA fluorescences of various treated MEFs were measured on the FITC 
channel. Averages of 8 total experiments are shown for all conditions except TUN treatment, 
which shows the average of 4 experiments. The p-values from two-tailed, paired t-tests are 
indicated. 
#
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In contrast to UV-treated MEFs, THP-treated WT MEFs were phagocytosed with 
significantly higher efficiency than THP-treated CRT deficient MEFs and untreated 
MEFs (Fig. 3.9A). The levels of target cell death were similar between WT and CRT 
deficient MEF target cells within a treatment group (Fig. 3.9C). Additionally, the level of 
dead target cells in the untreated group was least as high as that in the THP-treated group 
(Fig. 3.9C), a result which indicated that cell death in the THP-group was insufficient to 
account for the level of phagocytic uptake observed. Finally, although TUN treatment 
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enhanced phagocytic uptake of target cells relative to untreated cells, there was no CRT-
dependence to this effect, consistent with the inability to observe cell-surface CRT in 
TUN-treated cells (Fig. 2.1B and 2B). The fluorescence intensities of the various labeled 
target cells were similar, and could not explain the observed differences in the phagocytic 
indices (Fig. 3.9D). Taken together, these results suggest that THP-treated cells with 
measurable cell-surface CRT are phagocytosed in a manner that is partially CRT-
dependent.    
 
DISCUSSION 
 
Our results show that THP treatment of target cells increases pro-inflammatory 
cytokine production by BMDC in a manner independent of target cell-derived CRT (Fig. 
3.1), that extracellular CRT either in a cell-surface bound (Fig. 3.1) or soluble form (Fig. 
3.3 and data not shown) is unable to stimulate production of IL-1!, TNF-", IL-23 or IL-
12p70, and that THP treatment of cells impacts their phagocytic uptake in a CRT-
dependent manner (Fig. 3.9). 
Previous studies in HeLa cells have shown that NF-#B activation in response to 
agents that induce ER stress involves the release of calcium from the ER and the 
subsequent generation of ROS (reviewed in (Pahl and Baeuerle, 1997)). This mechanism 
likely accounts for sterile IL-6 production in response to direct THP treatments of BMDC 
(Fig. 3.6). THP is a stronger activator of the sterile IL-6 response than TUN (Fig. 3.6) 
likely due to a rapid effect of THP on cytosolic calcium elevation, whereas elevation of 
cytosolic calcium in response to TUN treatment may be more modest as well as 
kinetically delayed. Many recent studies have shown synergies between TLR-derived 
signals and transcription factors induced by the UPR, including XBP-1 and C/EBP 
homologous protein (CHOP). Of the cytokines measured in Figures 3.1 and 3.3, XBP-1 
was previously shown to synergize with TLR signals in enhancing IL-6 production by 
murine macrophages (Martinon et al., 2010). In human, monocyte-derived DC, CHOP 
binding to the IL-23p19 promoter enhanced IL-23 production in response to TLR ligation 
(Goodall et al., 2010).  
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Similar mechanisms could account for the synergy of ER stress signals and LPS 
in IL-23 production by BMDC (Fig. 3.6). We found that THP also strongly synergizes 
with LPS in the generation of IL-1! and IL-12p70. Recent findings showed that high 
avidity ligation of ITAM-containing receptors such as DAP12 can synergize with TLR 
signals to activate pro-inflammatory gene expression (reviewed in (Ivashkiv, 2008; 
Turnbull and Colonna, 2007)). High avidity ligation of DAP12 triggers an acute, transient 
calcium increase (reviewed in (Ivashkiv, 2008)). Here we show that, compared to TUN, 
THP treatment more strongly enhances various pro-inflammatory responses to LPS (Fig. 
3.6), consistent with similar findings from previous studies (Hsieh et al., 2007; Smith et 
al., 2008). These results point towards direct synergies between cytosolic calcium and 
TLR responses. Interestingly, it was suggested that ER calcium depletion could occur 
under certain conditions of ER overload and protein polymerization, even in the absence 
of classical UPR induction (Davies et al., 2009). Thus, findings described here may be 
relevant to a better understanding of inflammatory protein folding disorders that do not 
induce a classical UPR pathway.  
A truncated, bacterially-expressed, CRT construct was shown to induce TNF-" 
production by murine macrophages and human PBMC (Hong et al., 2010). N-terminal 
truncation of CRT induces self-association likely via the exposure of hydrophobic 
surfaces (Del Cid et al., 2010; Hong et al., 2010), and it is possible that protein truncation 
induces enhanced binding to bacterial pathogen-associated molecular patterns (PAMPs). 
We show here that full-length extracellular CRT derived from an endogenous source does 
not enhance the production of various pro-inflammatory cytokines in a THP-treated 
BMDC context (Figs. 3.1, 3.3 and data not shown). CRT is known to be present in the 
extracellular environment under a number of physiological conditions, and a number of 
extracellular functions are described for CRT (reviewed in Ref. (Gold et al., 2010)). 
Given these extracellular roles of the protein, the lack of innate immune induction by 
endogenously-derived, extracellular CRT is perhaps not surprising.  
BMDC phagocytosed CRT-high, THP-treated, target cells more efficiently than 
untreated cells in a manner partly dependent on CRT expression by the target cells (Fig. 
3.9). Experiments performed by Natasha Del Cid and myself (not shown) demonstrated 
that the level of target cell uptake and association (measured using co-incubations at 37 
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degrees) increased over time and eventually saturated. This supports the conclusion that 
this assay is in fact measuring phagocytic uptake. Correlating with undetectable levels of 
surface CRT in UV-treated cells, an effect of CRT on the phagocytosis of UV-treated 
cells was not observed (Fig. 3.9). In the UV-treated apoptotic cell context, other changes 
are expected that promote phagocytic uptake (reviewed in (Krysko and Vandenabeele, 
2008)), including the exposure of PS, which likely explain why significant uptake was 
observed in the absence of any CRT expression by the target cells (Fig. 3.9). 
Correspondingly, UV-treated target cells had a higher level of total association (i.e., the 
combination of uptake and adherence indicated by the 37
o
 C condition) with BMDC than 
any other target cell group (Fig. 3.10). This is likely the result of molecules that are 
upregulated on the surface of apoptotic cells and responsible for bridging apoptotic 
phagocytic cargo to potential phagocytes (reviewed in (Krysko and Vandenabeele, 
2008)). It is noteworthy that cell-surface CRT functions in the context of several other 
key eat-me and don’t-eat-me signals in viable and apoptotic cells (Gardai et al., 2005; 
Krysko and Vandenabeele, 2008; Park et al., 2008). The data of Figure 3.9 show that 
TUN-treated cells displayed enhanced phagocytic uptake compared to untreated cells, 
although this uptake was not CRT-dependent. This observation correlates with the 
absence of detectable cell-surface CRT in TUN-treated cells (Fig. 2.1B). The same level 
of uptake was seen with THP-treated, CRT-deficient cells (Fig. 3.9A). As shown in 
Figure 2.4, both TUN and THP significantly reduce cell-surface MHC-I. It is possible 
that interference with proper protein folding resulting from these treatments also 
decreases surface expression of don’t-eat-me signals like CD47 (Chao et al., 2010; 
Gardai et al., 2005) and plasminogen activator inhibitor-1 (PAI-1) (Park et al., 2008). 
This potential decreased surface expression of don’t-eat-me signals may explain the 
increased level of uptake of TUN-treated and THP-treated, CRT-deficient cells by 
BMDC.  
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Figure 3.10 UV-treated apoptotic cells have the highest level of association with 
BMDC of all target cell treatment groups.  
The values used to calculate the phagocytic indices shown in Fig. 3.9A (plotted there as the 
37°C/4°C ratios) are plotted here separately as percentages of CMFDA+ events in the CD11c+ 
gate at 4 °C and 37 °C.  
 
 In contrast to some previous findings (Obeid et al., 2007b), we show in this 
chapter that THP promotes phagocytic uptake of cells via mechanisms that are, in part, 
CRT-dependent. Thus the inability of THP-treated cells to induce anti-tumor immunity 
with sufficient potency (Martins et al., 2011; Obeid et al., 2007b) is likely not related to 
an absence of cell-surface CRT per se. Other immunogenic signals absent in THP-treated 
cells, including HMGB1 (Apetoh et al., 2007) and elevated levels of ATP (Ghiringhelli et 
al., 2009) (Fig. 3.5), may be required to confer stronger immunogenicity to treated cells. 
Consequently, although THP has some potentially desirable attributes for a 
chemotherapeutic, including the abilities to induce stronger phagocytic uptake of treated 
cells by DC (Fig. 3.9) and elicit stronger cytokine production by DC (Fig. 3.1 and 3.3), 
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these appear to be insufficient signals to confer anti-tumor immune protection (Martins et 
al., 2011). These observations are highly relevant to the ongoing clinical trials evaluating 
THP pro-drugs for the treatment of advanced solid tumors (ClinicalTrials.gov Identifier: 
NCT01056029, (Janssen et al., 2006)). Because phagocytic uptake and cytokine levels 
can influence T cell priming steps, our results highlight the importance of further research 
investigating the impacts of different forms of ER stress on the priming of CD8 and CD4 
T cell responses. 
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CHAPTER FOUR 
Discussion 
Given the range of necessary, basic cellular processes carried out by the ER, it is 
no surprise that deregulation or malfunction of the ER is associated with many diseases 
(Yoshida, 2007). Specifically, the connection between the ER stress response and 
diseases involving inflammation and autoimmunity generates much interest (Hummasti 
and Hotamisligil, 2010; Todd et al., 2008; Yoshida, 2007). Recent research suggests that 
parts of the ER stress response pathway are not only involved in excessive, disease-
related inflammation, but are also required for mounting a complete inflammatory 
response to defend against infection (Martinon et al., 2010). Additionally, because of the 
stressful environment within a tumor, the UPR is an important survival tool for many 
cancer cells (Healy et al., 2009). Clearly, the ER stress response is an important area of 
study for understanding the etiology of many diseases, including cancer (Healy et al., 
2009), neurodegenerative disorders (Yoshida, 2007), cardiovascular disease (Minamino 
et al., 2010), obesity and diabetes (Hummasti and Hotamisligil, 2010) and autoimmune 
diseases (Todd et al., 2008). Therefore, modulation of the ER stress response is a 
promising drug target for these and other diseases. Supporting this idea, some recent 
research retrospectively connects modulation of the ER stress pathway with mechanisms 
of action for pharmaceuticals currently in use (Obeid et al., 2007b; Yoshida, 2007).  
Within the cell, ER-resident chaperones and HSPs are important in mediating the 
ER stress response. Given that the HSP protein family is widely implicated in modulating 
the immune response in a variety of ways when present outside the cell (reviewed in 
chapter 1), studying the mechanisms of immunomodulation by extracellular HSPs in the 
context of ER stress may enhance understanding of the complex interactions between ER 
stress and inflammation. Furthermore, additional research on immunomodulation by 
HSPs is needed to guide the current and future clinical efforts to use extracellular HSPs 
to treat disease (Testori et al., 2008).  
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My thesis focused on understanding several biological aspects of extracellular ER 
chaperones and HSPs in the context of ER stress, with a primary focus on CRT, an HSP 
strongly implicated in phagocytosis of apoptotic cells and induction of anti-tumor 
immunity. Specifically, my thesis investigated mechanisms of chaperone release from the 
cell, the ability of the combined presence of several extracellular HSPs to influence 
innate immune responses, and the ability of extracellular CRT to enhance phagocytosis. 
In all three cases, we investigated these areas in the context of THP- or TUN-induced ER 
stress. 
Recently, the lab of Dr. Guido Kroemer characterized a stimulus-specific pathway 
for increased pre-apoptotic expression of cell-surface CRT (summarized in chapters 1 & 
2), induced by stimuli such as the chemotherapeutic MTX. This mechanism of cell-
surface CRT expression required calreticulin to be in complex with ERp57. However, 
other ER proteins were reported to be retained (with lysyl-tRNA synthetase [KARS] 
being the only exception (Kepp et al., 2010)). Furthermore, the mechanism described by 
Kroemer et al. involves transport of ERp57:CRT complexes through the secretory 
pathway in a manner that requires ER stress-induced PERK activation and ROS 
(Panaretakis et al., 2009). Finally, MTX treatment is reported not to induce detectable 
secretion of CRT despite high levels of CRT on the cell surface (Kepp et al., 2010). Prior 
to this study, Kroemer’s model for cell-surface CRT induction was the only published 
model for pre-apoptotic cell-surface CRT expression. We sought to further characterize 
cellular and molecular processes involved in cell-surface CRT induction with a focus on 
ER stress. 
In chapter 1, we characterize a novel pathway of transient, pre-apoptotic cell-
surface CRT expression in response to THP-induced, ER calcium depletion. Mechanisms 
of THP-induced, and MTX-induced, cell-surface CRT have some similarities, but several 
key differences in their characteristics. Following short exposures to drug, THP-induced 
cell-surface CRT levels were much higher than MTX-induced cell-surface CRT (Fig. 
2.1). Cell surface CRT was not detectable on the surface of apoptotic cells following long 
exposures to THP (Fig. 2.1). Cell-surface CRT expression in response to THP did not 
occur in all cell types examined (Fig. 2.4). Co-incident with short THP treatments, 
several ER chaperones are secreted: CRT, PDI, BIP and gp96 (Fig. 2.5). THP-induced 
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cell-surface CRT travels through the secretory pathway (Fig. 2.6). This finding rules out 
CRT transit through the cytosol, another recently proposed, but less-well characterized 
pathway for surface CRT expression on apoptotic cells (Tarr et al., 2010). In contrast 
with MTX, THP-induced cell surface CRT did not require the CRT:ERp57 interaction, 
and ERp57 was not detected on the cell surface (Fig. 2.7). Interestingly, we show that 
polypeptide binding by CRT was required for its retention on the cell surface (Fig. 2.9). 
Finally, we show that primary, apoptotic, plasma cells (a highly secretory, cell-type 
subject to acute and constitutive ER stress as part of its normal development and 
function), have high levels of cell-surface CRT easily detectable by flow cytometry. In 
our assays, cell surface CRT was not measurable on other apoptotic lymphocytes and 
splenocytes (Fig. 2.9-11) and a variety of other cell types tested (Fig. 2.1). These studies 
show that increases in cell-surface CRT expression can occur by mechanisms other than 
ERp57 co-transport, and that a measurable up-regulation of cell-surface CRT is not a 
universal feature of apoptotic cells. 
Our published work shows that THP treatment leads to a greater induction of pre-
apoptotic cell-surface CRT than MTX treatment (Peters and Raghavan, 2011b). The work 
of Kroemer et al. showed the opposite trend (Obeid et al., 2007b). Because of this 
contrast, we tested the effects of primary antibody, cell line, fixation of stained cells, and 
solvent used for mitoxantrone solution on cell surface CRT induction. Variations in 
experimental techniques included using the same anti-calreticulin antibody used in Obeid 
et al 2007, the same cell line used in the majority of Kroemer’s work (CT26), using a 
different solvent to reconstitute the MTX, and experiments with and without fixation of 
the stained cells. Similar levels of CRT induction were obtained using the rabbit-anti-
CRT antibody (Abcam) used by Kroemer and colleagues or chicken-anti-CRT (Affinity 
Bioreagents) antibody used by Gardai and colleagues (Gardai et al., 2005). Consequently, 
Figures 2.1 and 2.2 include experiments performed with both antibodies (as described in 
the materials and methods). Additionally solublizing MTX in ethanol instead of DMSO 
did not lead to higher CRT induction by MTX (data not shown). The data shown used 
MTX reconstituted in DMSO. However, we performed additional and experiment with 
MTX in ethanol. This did not improve the relative induction of cell-surface CRT by 
MTX (data not shown). Furthermore, cell-surface CRT induction in CT-26 cells was 
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unaltered by fixation of the stained cells (data not shown). We conclude that the 
described differences in our cell-surface CRT induction data compared to that published 
by Kroemer and colleagues are not due to the described experimental variations. 
However, there were procedural differences in the cell death stains in our protocol that 
may explain some of the discrepancy in the data (ie. Our cells were triple stained with 
CRT, a permability marker and Annexin-V).  
Identifying conditions that induced cell-surface CRT expression and secretion of 
several ER chaperones (chapter 2), allowed us to investigate extracellular functions of 
several HSPs (chapter 3). Specifically, we examined whether or not CRT-high, THP-
treated cells induced production of several cytokines by BMDC, or suppressed BMDC 
cytokine production in response to LPS. This is of great interest because several of the 
ER chaperones secreted by THP-treated cells are reported to strongly modulate the innate 
immune response in other experimental or physiological systems. Furthermore, cell-
surface CRT is widely reported to have a very active role in inducing anti-tumor immune 
responses (reviewed in (Tesniere et al., 2008)). The use of WT & CRT
-/-
 MEFs in our 
experiments directly assessed the contribution of the innate immune response to the role 
of cell-surface CRT in anti-tumor immunity. Finally, we examined phagocytic uptake by 
an APC (BMDC) of target cells subjected to two different types of ER stress and the 
effect of CRT expression by the target cells (Fig. 3.9).  
We show that THP-treated cells and CM stimulate sterile production of IL-6, but 
not IL-1!, IL-12p70, TNF-", and IL-23 despite the extracellular presence of BIP, CRT, 
gp96 and PDI (Fig. 3.1 and 3.2). Furthermore, the extracellular presence of these HSPs 
with or without THP-treated cells did not dampen production of IL-1!, IL-12p70, TNF-
", and IL-23 by BMDC in response to LPS (Fig. 3.1 and 3.2). Interestingly, the LPS-
induced production of IL-1!, IL-12p70, TNF-", and IL-23 was dramatically increased 
following co-incubation with THP-treated cells or cell CM (Fig. 3.1 and 3.2). 
Importantly, none of the cytokine responses measured were altered by or dependent on 
CRT expression by the THP-treated cell (Fig. 3.1 and 3.2). BMDC co-incubations with 
THP-treated target cells were compared to co-incubations with MTX and TUN-treated 
cells, and neither of the latter two conditions altered innate immune responses by BMDC 
(Fig. 3.1 and 3.2). This is quite relevant in understanding the ability of MTX-treated cells 
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to stimulate protective and therapeutic anti-tumor immune responses when injected into 
mice. Our data suggests for the first time, that the immunogenicity of MTX-treated tumor 
cells may be limited to its influence on the adaptive immune response (Obeid et al., 
2007b). Of equal or greater importance, we used drug-treated (MTX and THP) WT and 
CRT
-/-
 target cells as potential stimuli for BMDC cytokine production. In doing so, we 
convincingly demonstrated that the important role cell-surface CRT plays in inducing an 
anti-tumor immune response does not involve its stimulation of pro-inflammatory 
cytokine production by DC. An important next step of these experiments is to evaluate 
whether other APC subsets respond differently to cell-surface CRT in vitro and in vivo. 
In order to further understand the mechanism by which THP-induced ER stress in 
target cells stimulated BMDC cytokine production in a paracrine manner, we compared 
BMDC responses to direct treatment with the two ER stress inducers TUN & THP (Fig. 
3.6). These analyses showed that both a direct TUN or THP treatment of BMDC induce 
cytokine expression with a similar pattern as that observed with THP-treated cells and 
cell CM (Fig. 3.1 and 3.3). However, THP more strongly enhanced LPS-induced 
expression of IL-1! and much more strongly (~10 fold) induced sterile IL-6 production 
than TUN (Fig. 3.6). Several effects downstream of the (likely) stronger and faster 
calcium flux induced by THP (relative to TUN) may explain the difference in IL-1! and 
IL-6 production. Consistent with this possibility, Hsieh et al. showed that THP induced 
over 2 fold more ROS than TUN treatment of NIH3T3 MEFs. This was attributed in part 
to the strong calcium efflux from the ER and/or an ER overload response (EOR) induced 
by THP-treated cells (Hsieh et al., 2007). Notably, ROS influence many signaling 
pathways. In particular, ROS can induce NF#B translocation to the nucleus (ie. 
activation) by promoting the degradation of its endogenous inhibitor I#B (Chen et al., 
2009). Therefore, increased ROS induced by THP is likely to lead to increased NF#B 
activation and subsequent increased IL-6 production though this mechanism, and 
possibly others. ROS also control the priming of the NLRP3 inflammasome, which is 
required for mature IL-1! secretion following LPS addition (Bauernfeind et al., 2011). 
Again, the increased levels of ROS induced by THP relative to TUN are implicated in the 
enhanced pro-inflammatory profile induced by THP treatment of BMDC. These findings 
are relevant to understanding inflammatory protein folding disorders involving ER 
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calcium depletion as a result of an EOR (Davies et al., 2009; Pahl and Baeuerle, 1997) in 
the presence or absence of a classically defined UPR (discussed in more depth below).  
We next sought to characterize the stimulatory factor(s) released from THP 
treated cells. We first examined the release of the known endogenous DAMPs HMGB1 
and ATP. These analyses suggested that ATP and HMGB1 are not responsible for the 
stimulation induced by THP-treated cells (Fig. 3.6B-D). BMDC had similar responses to 
direct THP treatment and to paracrine stimulation by washed, THP-treated target cells 
(and cell CM). Therefore, we investigated whether the washed, THP-treated cells 
released soluble THP molecules, resulting in direct BMDC stimulation by dialyzing THP 
CM. We established that the paracrine stimulatory factor(s) released from THP-treated 
target cells was/were larger than 10 kDa (Fig. 3.7). Because THP monomers have a 
molecular mass of 650 Da, these findings suggest the paracrine stimulatory factor(s) 
is/are likely one or more of the following: 1) an unmodified (or stress-modified) 
endogenous DAMP/stimulatory factor released from the THP-treated target cells; or 2) 
residual THP either bound to other molecules with a larger molecular mass or in 
multivalent complexes larger than 10 kDa (Fig. 3.7). Scenario 1 could still potentially be 
involved in the stimulation of BMDC by direct THP treatment by release of factors and 
their acting in an autocrine or paracrine manner in the BMDC culture. 
Several lines of evidence discussed in chapter 3 lead us to favor the idea that THP 
molecules themselves are responsible for the stimulation of BMDC by THP-treated cells 
or CM from THP-treated cells. Notably, qualitatively, cytokine production resulting from 
ER stress occurring within TUN-treated DC was similar to that in THP-treated DC 
(chapter 3), and my work in chapter 2 showed that TUN does not induce release of 
suspected DAMPs (HSPs). This conclusion is in agreement with recent publications 
showing that various ER stress stimuli (not associated with a failure in ER retention) 
synergize with LPS ligation in macrophages and B-cells resulting in greatly enhanced 
cytokine production (DeLay et al., 2009; Goodall et al., 2010; Martinon et al., 2010; 
Smith et al., 2008). Building on these observations, Martinon et al. showed that activated 
XBP-1 plays a role in enhancing pro-inflammatory cytokine production in response to 
PRR ligation that is independent from its role in inducing UPR (Martinon et al., 2010). 
This role for XBP-1s was not demonstrated for sterile IL-6 production during ER stress, 
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however, it may still be relevant to my observations of sterile IL-6 production in response 
to THP & TUN (chapter 3). Together, my results suggest that any endogenous factors 
released from THP-treated target cells, such as the HSPs BIP or gp96, are unable to 
significantly suppress or induce innate immune responses. This possibility is consistent 
with the inability of cell-surface (Fig. 3.1) or secreted (Fig. 3.3) CRT to influence innate 
immune responses, examined more directly with CRT
-/-
 MEFs.  
Interestingly, we showed that BMDC phagocytosed ER stressed target cells at 
levels significantly above background uptake of dead cells in the UNT target control 
(Fig. 3.9-3.10). As shown in Figure 3.9C the average levels of viable [AnnV(-), & 
7AAD(-)] cells is 82-91% for the UNT, TUN & THP target cells and 22-23% for UV-
treated apoptotic cells. It is interesting to speculate that with THP and TUN-treated target 
cells, we observed PS-independent phagocytic uptake of the viable cells rather than PS-
dependent uptake of the 10-20% of dead cells. Although our experiments did not directly 
test this possibility, comparing the relative levels of dead cells and phagocytosis under 
each condition suggests PS-independent uptake of viable cells. As indicated in chapter 3, 
if phagocytic uptake of these viable, ER stressed cells is occurring, it is likely due to the 
down-regulation of don’t eat me signals. 
We showed in chapter 2 that TUN & THP caused significant down-regulation of a 
constitutively-expressed cell surface protein, MHC-I (Fig. 2.4). Although MHC-I is not a 
‘don’t eat me’ signal, this observation demonstrates that ER stress results in the down-
regulation of at least one cell-surface protein. This observation is consistent with the 
hypothesis that a don’t eat-me signal could be down-regulated by ER stress. Furthermore, 
the UPR-induced block in translation of non-essential proteins [reviewed in (Todd et al., 
2008)] is a potential cause of down-regulation of some cell-surface proteins during ER 
stress. Another potential mechanism of down-regulation of specific cell-surface proteins 
during ER stress may be the induction of specific ‘sheddases.’ Sheddases, such as 
members of the “A Disintegrin And Metalloprotease” (ADAM) family can 
proteolytically cleave the ecto-domain of integral membrane proteins. It is possible that 
ER stress induces shedding of specific cell-surface proteins by altering the expression or 
activation of sheddases. Knock-out mice exist for several ADAM family members 
(reviewed in (Reiss and Saftig, 2009)). Use of cells from these mice would allow 
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examination of the role of various ADAM family members in down-regulation of 
constitutively expressed cell-surface proteins in response to ER stress. In conclusion, ER 
stress may down-regulate ‘don’t-eat me’ signals through various mechanisms, and further 
investigations of these observations are needed.  
Other papers demonstrated phagocytic uptake of live cells by blocking ‘don’t eat-
me’ signals or receptors for ‘don’t eat me’ signals (Chao et al., 2010; Gardai et al., 2005; 
Park et al., 2008). However, to my knowledge, our work provides the first suggestion that 
ER stress could potentially promote phagocytic uptake by APCs via interference with 
expression of don’t eat me signals. This possibility has interesting implications for the 
maintenance of peripheral tolerance and the loss of peripheral tolerance and deserves 
further study. Specifically, the ability of various types of ER stress to down-regulate 
known don’t-eat me signals should be examined. 
In order for PS-independent phagocytic uptake to occur, eat-me signal(s) must be 
present on the cell surface. Although we didn’t detect distinctive signals for cell-surface 
CRT in most situations we examined using flow cytometry, most papers examining 
viable cells by microscopy show CRT on the surface of viable cells (Gardai et al., 2005; 
Kuraishi et al., 2007; Obeid et al., 2007a; Panaretakis et al., 2009; Park et al., 2008; Tufi 
et al., 2008). Therefore, it is possible that cell-surface CRT may play a role in the uptake 
of TUN cells, despite the fact that we did not detect surface CRT by flow cytometry. 
Supporting this idea, TUN WT cells’ total association (37 degree condition) with BMDC 
was higher than that seen with TUN CRT
-/-
 cells (Fig. 3.9 – 37 degree condition), 
although this difference did not achieve statistical significance (p=0.0872, n=4) (Fig. 
3.9). As described earlier, total association is a measure of the target cells adhered to the 
outside of the BMDC (measured by co-incubations at 4
o
C) and the target cells 
phagocytosed by BMDC. In the context of TUN-treated cells, CRT may act to bridge 
targets to BMDC. These types of differences were not detected with the UV-treated 
targets (Fig. 3.9), where phosphatidylserine exposure and other cellular changes could 
promote bridging and uptake. The experiments of Figures 3.9 & 3.10 showed a relatively 
high degree of variation due in large part to the relatively low phagocytic indices when 
measuring BMDC phagocytosis of target cells by this assay. The magnitudes of our 
phagocytic indices are consistent with previously published examples of these assays 
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(Kopecka et al., 2011; Obeid, 2008; Obeid et al., 2007b). The low positive signal results 
in a greater influence of natural experimental variability. Furthermore, data measuring 
phagocytic uptake of TUN-treated (n=4) and UV-treated (n=8) CRT
-/-
 targets were 
particularly variable. These factors considered, it remains possible, or even likely, that 
cell-surface CRT plays a role in the uptake of TUN-treated cells.  
In the context of a different type of ER stress (THP-induced ER calcium 
depletion) a role for cell-surface CRT in inducing uptake by BMDCs is quite 
unambiguous. We showed that BMDC phagocytosed CRT high, ER calcium-depleted 
cells at levels similar to those of UV-treated apoptotic cells, in a manner significantly 
enhanced by CRT (Fig. 3.9-3.10). It should be noted that ~80% of the UV-treated 
apoptotic cells were positive for the strong eat-me signal PS (Fig. 3.9C). As mentioned, 
Figure 3.9 indirectly suggests that PS-negative viable THP-treated cells are phagocytosed 
by BMDC. Consistent with this possibility, other reports suggest that BMDCs can 
phagocytose CRT-high, PS negative cells in the context anthracyclin-treated pre-
apoptotic cells (Obeid, 2008; Obeid et al., 2007b).  
Our report of high levels of cell-surface CRT significantly enhancing uptake of 
THP-treated (likely PS negative) cells is also consistent with CRT’s described role as an 
‘eat-me’ signal on the surface of apoptotic, PS positive cells (Gardai et al., 2005; 
Kuraishi et al., 2007). However macrophages or fibroblasts were used as the phagocytes 
in the previous demonstration of CRT-dependent uptake of mammalian apoptotic cells 
(Gardai et al., 2005). CRT dependent uptake of apoptotic cells was also described in 
Drosophila, but it is already known that PS is not used as an eat-me signal in Drosophila 
(Kuraishi et al., 2007). Therefore, to my knowledge, our analysis of the relative 
contributions of PS-mediated uptake and CRT-mediated uptake of mammalian UV-
treated apoptotic cells is the first such examination with DC (Fig. 3.9-3.10). Although we 
weren’t able to measure UV-induced increases in cell-surface CRT by flow (Fig. 3.9B), it 
is quite possible that some cell-surface CRT is present. As discussed, evaluations of UNT 
cells often detect only background levels of cell-surface CRT by flow (similar to what we 
see with UNT cells and UV-treated cells) (Obeid, 2008; Obeid et al., 2007b), yet 
fluorescence microscopy typically reveals cell-surface CRT on UNT neutrophils and 
transformed cell lines (Gardai et al., 2005; Obeid et al., 2007a; Paidassi et al., 2011; 
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Panaretakis et al., 2009; Park et al., 2008; Tufi et al., 2008). These observations support 
the idea that although we didn’t detect any specific increases in CRT surface expression 
following UV-treatment, it may still be present on the surface. This possibility is further 
supported by findings from at least two other groups that UV induces CRT cell-surface 
expression (Gardai et al., 2005; Obeid et al., 2007a; Paidassi et al., 2011).  
Regardless, our analysis of uptake of UV WT & CRT
-/-
 MEFs by BMDC reveals 
the important finding that BMDC are not dependent on CRT expression in the target cell 
for uptake of apoptotic cells. However, these experiments must be conducted in other DC 
subsets to confidently extend these conclusions into in vivo situations. As mentioned, 
macrophage (J774, peritoneal, and human-monocyte derived)-mediated phagocytosis was 
suggested to be highly dependent of CRT expression in apoptotic target cells (Gardai et 
al., 2005), which contrasts with our findings in BMDC. In many cases, DC and not 
macrophages are the cells responsible for professional antigen presentation during T-cell 
priming (reviewed in (Savina and Amigorena, 2007)). Therefore, more research 
investigating the relative contributions of PS and CRT-mediated signaling in the 
phagocytic uptake of apoptotic cells by various DC subsets is needed. Such studies would 
contribute to the understanding of mechanisms of DC-induced peripheral tolerance and 
adaptive immune responses to cell-associated antigens. 
More questions remain regarding precisely how cell-surface CRT expression on 
dying tumor cells drives the anti-tumor immune responses reported by Kroemer and 
colleagues (reviewed in (Zitvogel et al., 2010)). My work clearly demonstrates that cell 
surface CRT does not induce proinflammatory cytokine expression by BMDC (chapter 
3). In the absence of PS surface exposure CRT surface expression significantly enhances 
uptake of targets by DC (chapter 3, this thesis and (Obeid et al., 2007b)). However, my 
work shows for the first time that BMDC (or any DC subset) uptake of apoptotic cells 
killed by UV light is not affected by CRT expression in the target cell. This finding 
suggests that CRT may not enhance delivery of apoptotic-cell associated antigens to DC. 
However, different DC subsets could differ in expression of CRT specific receptors and 
in their abilities to mediate CRT-dependent uptake of apoptotic targets. 
Consequently, the recent finding that lymph node resident, CD11c+CD169+ 
‘macrophages’ are required for cross-priming anti-tumor immune responses to 
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subcutaneously injected apoptotic tumor cells is particularly interesting (Asano et al., 
2011). Subcutaneous vaccination is the route used to show that surface CRT-high dying 
tumor cells are highly immunogenic (Obeid et al., 2007b). In contrast, a 
CD8"+CD103+CD207+ DC subset in the spleen was recently suggested to be 
responsible for tolerance induction to blood-born apoptotic cells (Qiu et al., 2009). PS 
exposed on apoptotic cells is known to be dominantly immunosuppressive and cell-
surface CRT is required for induction of many experimentally induced, protective anti-
tumor immune responses (Green et al., 2009). Therefore I propose that the APC subsets 
responsible for generating tolerance to cell-associated antigens (such as splenic 
CD8"+CD103+CD207+ DC) receive PS-mediated signals from apoptotic cells that 
promote T-cell tolerance to presented antigens. Furthermore, I propose that APC subsets 
responsible for activating T-cells specific to cell-associated antigens (such as LN-resident 
CD11c+CD169+ macrophages), preferentially receive signals from apoptotic cell-surface 
CRT (rather than PS) that enhance T-cell activation against presented antigens. The 
signals from cell-surface CRT may alter antigen processing and presentation, or may 
simply prevent PS-mediated immunosuppression. An important note in considering my 
proposed model, is that Qiu et al. showed uptake of apoptotic cells by CD11c+CD169+ 
macrophages was PS-dependent. To suggest this, they showed that blockade of PS on 
apoptotic target cells with a mutant MFG-E8 blocked apoptotic cell uptake (Asano et al., 
2011). However CRT co-localizes with PS in clusters on the apoptotic cell surface 
(Gardai et al., 2005), so it is possible that protein binding to PS sterically blocks access of 
macrophage receptors for CRT on the apoptotic cell surface. In conclusion, my results 
showing CRT-independent phagocytosis of apoptotic cells by DCs warrant further 
investigation on how different ‘eat-me’ signals differentially effect antigen presentation 
by various APC subsets.     
 
Thapsigargin as a chemotherapeutic 
 Unlike many current chemotherapies that are cytotoxic to proliferating cells, 
thapsigargin is cytotoxic to both proliferating and quiescent cells (ie., cells in growth 
arrest) (Denmeade et al., 2003). Some cancers, such as prostate cancer, have many non-
proliferative or slowly proliferative cells (Denmeade et al., 2003). Furthermore, some 
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prostate cancer cells are resistant to a current therapeutic regiment of choice because of a 
lack of a sustained rise in intracellular calcium (and subsequent apoptosis) in response to 
a current treatment. These observations led to the development of thapsigargin prodrugs 
that are targeted to prostate cancer cells. Phase I clinical trials are currently evaluating 
dosage and pharmacokinetics of targeted THP pro-drugs in patients with advanced solid 
tumors (ClinicalTrials.gov Identifier: NCT01056029, (Janssen et al., 2006)).  
Because apoptosis is usually immunosuppressive, the search of 
chemotherapeutics that induce immunogenic cell death is of interest. The pursuit of 
clinical applications for THP was part of the justification for the work described in this 
thesis that investigated the immunological consequences of thapsigargin. The previous 
work from G. Kroemer and colleagues suggests that thapsigargin does not induce 
immunogenic cell death in mouse tumor immunization models (Martins et al., 2011; 
Obeid et al., 2007b). However, in Kroemer’s studies, THP-treated tumor cell vaccines 
induced tumor growth in the vaccination flank (Martins et al., 2011). This finding 
suggests that the preparation contained too many live cells and this needs to be re-
examined. 
My work contributes to knowledge about the potential immunological properties 
of thapsigargin-mediated cell death. I showed that thapsigargin induces high levels of 
cell-surface calreticulin (chapter 2), phagocytic uptake of treated cells, and pro-
inflammatory cytokine production by BMDC (chapter 3). Despite these effects, THP-
treated tumor cells may prove not to be a stimulator of anti-tumor immunity for several 
reasons.  
First, Torchinski et al. showed phagocytosis of infected apoptotic cells by DC 
resulted in production of IL-6 and TGF-! (Torchinsky et al., 2010). Furthermore, 
Torchinski et al. showed that the conditioned media from these DC induced 
differentiation of naïve CD4 T-cells into a FoxP3(-), IL-10 producing 
immunosuppressive T-cell subset (in addition to the Th17 cells induced by the 
conditioned media from the described DC, which was the focus of the paper) (Torchinsky 
et al., 2010). Relevant to this, I showed that BMDC exposed to THP or THP-treated cells 
produce sterile IL-6 (chapter 3). As mentioned, a vaccine with THP-killed tumor cells 
cannot have any pre-apoptotic cells or it will induce the growth of a tumor in the 
  
 112 
vaccination flank prior to the induction of an immune response (Martins et al., 2011). 
Therefore, vaccination with THP-killed cells will likely have mostly PS-positive 
apoptotic cells that lack high levels of cell-surface CRT (chapter 2). The BMDC or 
macrophages phagocytosing these THP-treated tumor cells may produce TGF-! in 
response to the PS (reviewed in (Green et al., 2009)). Consequently, APC phagocytosing 
apoptotic THP-treated cells may drive the differentiation of tumor-specific CD4-T-cells 
into an IL-10 producing immunosuppressive phenotype. However, in a more clinically 
relevant therapeutic system (or in the clinical trials), the THP-killed tumor cells may be 
phagocytosed prior to PS-exposure due to a high-level of pre-apoptotic cell-surface CRT 
(chapter 2). In this situation, it is possible that TGF-! would not be produced and 
effective anti-tumor immune responses may be induced. The second reason THP may not 
prove to be an immunogenic chemotherapeutic is due to high levels of NO shown by 
others to be induced by THP (Hsieh et al., 2007). This is suggested because NO 
production by iNOS activation in DC was recently shown to be required for apoptotic 
cell-mediated immunosuppression by DC (Ren et al., 2008). However, these studies used 
dexamethasone-induced apoptosis that may not induce cell-surface CRT. Additionally, a 
different group recently showed that iNOS activation and subsequent NO production in 
anthracyclin-treated tumor cells was required for cell-surface CRT expression and 
phagocytic uptake by DC (De Boo et al., 2009). It is likely that the effects of NO 
production in DC are context specific, and is a possibility that requires further 
investigation. The final reason THP may not prove to be an immunogenic 
chemotherapeutic in some situations is that its ability to induce high levels of cell-surface 
CRT appears to be cell-type specific. Therefore it is of interest to characterize the 
immunogenicity of more clinically-relevant cell-types (prostate cancer cells) treated with 
THP. As a first step, we showed that human multiple myeloma’s (RPMI8226 and H929) 
do not show detectable THP-induced increases in cell-surface CRT (Fig. 2.2B).         
 
ER calcium depletion and inflammatory disorders 
Together, this work identifies important differences between ER stress that is 
induced primarily by protein misfolding (due to pharmacological inhibition of the ER 
glycosylation machinery (TUN)) versus that induced primarily by ER calcium depletion 
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(due to inhibition of calcium uptake into the ER (THP)). Primarily we showed that THP 
but not TUN treatment induces a global handicap in ER retention leading to abnormal 
secretion (and surface expression in some cases) of ER resident proteins (chapter 2). 
Furthermore, direct THP treatment of BMDC induces ~10 fold more sterile IL-6 and ~2 
fold more LPS-stimulated IL-1! production than TUN treatment, (Fig. 3.6). These 
observations suggest that these two drugs may elicit different types of ER stress.  
The idea that THP and TUN-mediated ER stress are distinct is consistent with a 
model originally proposed in 1995, wherein the ER responds differently to overload 
occurring in the absence of protein misfolding (EOR), than it does to accumulation of 
misfolded proteins in the ER (UPR) (Pahl and Baeuerle, 1995). The EOR model consists 
of ER overload leading to ER calcium depletion, reactive oxygen species generation and 
activation of NF#B (Pahl and Baeuerle, 1996). The existence of an EOR that doesn’t 
induce the UPR was supported by some early observations surrounding the accumulation 
of a clinically relevant mutant anti-trypsin protein in the ER of hepatocytes. Specifically, 
in 1990, Graham et al. showed that mutant protein accumulation in the ER did not lead to 
upregulation of BIP (one of many downstream effects of UPR activation) yet did lead to 
NF#B activation (Graham et al., 1990). However, PERK activation by ER stress also 
leads to NF#B activation, and a lack of BIP upregulation did not entirely rule out 
activation of the UPR (Deng et al., 2004). Furthermore, many of the stimuli used to 
initially characterize the EOR (Pahl and Baeuerle, 1996) are also now known to induce 
UPR. Therefore, for many years, it was difficult to identify physiological (or convincing 
experimental) conditions where the ER becomes overloaded, yet does not have an 
accumulation of misfolded proteins, and has a stress response distinct from the UPR. 
Because of this, research on, and understanding of, the EOR is less extensive than that of 
the UPR. 
Recently, however, the existence of an ‘EOR’ completely distinct from the UPR 
was confirmed (Davies et al., 2009; Hidvegi et al., 2005). Study of familial dementia 
caused by mutant neuroserpin proteins that accumulate and polymerize in the ER 
revealed an EOR completely independent from the UPR (Davies et al., 2009). Like the 
originally proposed EOR (Pahl and Baeuerle, 1996), Davies et al. showed that the 
activation of NF#B (a transcription factor involved in the induction of immune 
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responses) in response to mutant neuroserpin accumulation in the ER required ER 
calcium flux into the cytosol (Davies et al., 2009). Furthermore, inflammation is 
associated with the etiology of dementia caused by mutant neuroserpin EOR (Leonard, 
2007). My data in Figure 3.6 suggest that the ER calcium flux associated with EOR is 
likely much more pro-inflammatory than UPR, which supports the view that an EOR is 
an important factor driving the pathogenic inflammation in this disease and other diseases 
where an EOR is implicated.  
In atherosclerosis, ER overload of a different kind is implicated in inducing 
inflammation. Macrophages in atherosclerotic plaques take up free cholesterol (FC). This 
leads to an abnormal increase (‘overload’) in the cholesterol composition of the ER 
membrane known as membrane ‘stiffening’ (Li et al., 2004). Such stiffening is suggested 
to inactivate SERCA by increasing the structural order of the ER membrane and 
restricting the movement of SERCA (Li et al., 2004). Interestingly, in the model of 
neuroserpin polymer accumulation in the ER, Davies et al, proposed that ‘Ordered 
Protein Response’ (OPR) was a better term than EOR to describe the effects of 
neuroserpin accumulation in the ER (Davies et al., 2009). Their use of the term ‘order’ 
suggests that increased ER order (or restriction of fluidity) is a common mechanism 
driving ER-induced inflammation in atherosclerosis and other OPR-related diseases. 
As in diseases associated neuroserpin-induced OPR, inflammation also plays a 
role in the pathogenesis of atherosclerosis. Inflammation in atherosclerotic plaques is 
linked to 2/3 of heart attacks and strokes by promoting plaque rupture (Charo and Taub, 
2011). Furthermore, IL-6 controls expression of genes positively linked to the risk of 
atherosclerosis (Brasier, 2010). In the case of atherosclerosis, the SERCA inhibition 
induced by increased order of the ER was implicated in inducing inflammatory cytokines 
IL-6 & TNF-" (Li et al., 2005). In the case of atherosclerosis, UPR is induced (Feng et 
al., 2003), unlike during neuroserpin accumulation in the ER where OPR is suggested to 
occur independently of UPR (Davies et al., 2009). However, because inhibition of 
SERCA is the proposed mechanism leading to FC-loaded stress in atherosclerosis, it 
would most likely resemble THP treatment, and have an OPR and UPR.  
My data comparing pro-inflammatory responses of BMDC subjected to TUN or 
THP-induced ER stress, suggests that FC loading of the macrophage ER membrane 
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occurring during atherosclerosis would result in much more sterile IL-6 production than 
compared to a situation where UPR alone is responsible for the inflammation detected. 
Furthermore, it is possible that macrophages in atherosclerotic plaques exhibit the other 
THP-induced phenotypic characteristics I have described: loss of ER retention and 
synergistically enhanced LPS-induced cytokine production (and possibly primed NLRP-3 
inflammasomes). These potential consequences of FC loading may further contribute to 
atherosclerosis and should be investigated. Currently, it is unknown what signals link 
Davies et al.’s proposed OPR during neuroserpin polymerization within the ER, to ER 
calcium depletion. However, experiments measuring the freedom of SERCA movement 
in neuroserpin-induced ER overload may reveal that it is the increase in ER order that 
causes SERCA inhibition in a mechanism similar to that seen in FC-loaded macrophages. 
 
ER stress, tolerance and autoimmunity 
As stated previously, although my data suggest that HSPs like CRT, gp96 and BiP 
do not stimulate innate immune responses, it supports a role for promoting presentation 
of cell-associated antigens to T-cells through enhanced phagocytic antigen delivery to 
APCs (chapter 2). Some research investigators occasionally speculate about the 
involvement of extracellular CRT (Eggleton and Llewellyn, 1999) and gp96 (Han et al., 
2010) in the pathogenesis of autoimmune diseases such as lupus and rheumatic arthritis. 
It is interesting to hypothesize what physiological conditions might induce the loss of ER 
retention in a stressed target cell (chapter 1), and sterile inflammatory cytokine 
production by a surrounding APC (chapter 2). The first question to answer is whether or 
not a physiological source of ER calcium depletion, such as an EOR/OPR, induces cell-
surface CRT. This could promote uptake of a PS-negative, self-cell, subverting the 
typical immunosuppressive effects of PS-mediated uptake. However, in most situations 
this would promote peripheral tolerance through clonal deletion of the Ag-specific T-cell 
by presentation of antigen in the absence of co-stimulation. However, if the APC is also 
subjected to any type of ER stress (such as expression of some mutant proteins (Davies et 
al., 2009; Smith et al., 2008), a UPR (Martinon et al., 2010) (Chapter 3), or overload of 
the ER membrane with cholesterol (Li et al., 2005)), it will have likely have NF#B 
activation and produce IL-6. This combination may lead to presentation of self-antigens 
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by a mature APC expressing co-stimulatory molecules, and clonal expansion of a self-
reactive T-cell. Obviously there are other checks and balances in place to prevent a loss 
of self-tolerance, but experiments directed at investigating some of these ideas may 
contribute to our understanding of autoimmunity. 
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